Many modules are hidden in this stack. Use "module --show_hidden spider SOFTWARE" if you are not able to find the required software
# packages in environment at /cluster/home/gcardenal/miniconda3/envs/vllm:
#
# Name                    Version                   Build  Channel
_libgcc_mutex             0.1                        main  
_openmp_mutex             5.1                       1_gnu  
accelerate                1.1.1                    pypi_0    pypi
aiohappyeyeballs          2.4.0                    pypi_0    pypi
aiohttp                   3.10.6                   pypi_0    pypi
aiosignal                 1.3.1                    pypi_0    pypi
annotated-types           0.7.0                    pypi_0    pypi
anthropic                 0.40.0                   pypi_0    pypi
anyio                     4.6.0                    pypi_0    pypi
argon2-cffi               23.1.0                   pypi_0    pypi
argon2-cffi-bindings      21.2.0                   pypi_0    pypi
arrow                     1.3.0                    pypi_0    pypi
asttokens                 3.0.0                    pypi_0    pypi
async-lru                 2.0.4                    pypi_0    pypi
async-timeout             4.0.3                    pypi_0    pypi
attrs                     24.2.0                   pypi_0    pypi
babel                     2.16.0                   pypi_0    pypi
beautifulsoup4            4.12.3                   pypi_0    pypi
bleach                    6.2.0                    pypi_0    pypi
bzip2                     1.0.8                h5eee18b_6  
ca-certificates           2024.7.2             h06a4308_0  
certifi                   2024.8.30                pypi_0    pypi
cffi                      1.17.1                   pypi_0    pypi
charset-normalizer        3.3.2                    pypi_0    pypi
click                     8.1.7                    pypi_0    pypi
cloudpickle               3.0.0                    pypi_0    pypi
comm                      0.2.2                    pypi_0    pypi
datasets                  3.0.1                    pypi_0    pypi
debugpy                   1.8.9                    pypi_0    pypi
decorator                 5.1.1                    pypi_0    pypi
defusedxml                0.7.1                    pypi_0    pypi
dill                      0.3.8                    pypi_0    pypi
diskcache                 5.6.3                    pypi_0    pypi
distro                    1.9.0                    pypi_0    pypi
einops                    0.8.0                    pypi_0    pypi
emoji                     2.14.0                   pypi_0    pypi
exceptiongroup            1.2.2                    pypi_0    pypi
executing                 2.1.0                    pypi_0    pypi
fastapi                   0.115.0                  pypi_0    pypi
fastjsonschema            2.21.1                   pypi_0    pypi
filelock                  3.16.1                   pypi_0    pypi
fqdn                      1.5.1                    pypi_0    pypi
frozenlist                1.4.1                    pypi_0    pypi
fsspec                    2024.6.1                 pypi_0    pypi
gguf                      0.10.0                   pypi_0    pypi
h11                       0.14.0                   pypi_0    pypi
httpcore                  1.0.5                    pypi_0    pypi
httptools                 0.6.1                    pypi_0    pypi
httpx                     0.27.2                   pypi_0    pypi
huggingface-hub           0.25.1                   pypi_0    pypi
idna                      3.10                     pypi_0    pypi
importlib-metadata        8.5.0                    pypi_0    pypi
interegular               0.3.3                    pypi_0    pypi
ipykernel                 6.29.5                   pypi_0    pypi
ipython                   8.30.0                   pypi_0    pypi
ipywidgets                8.1.5                    pypi_0    pypi
isoduration               20.11.0                  pypi_0    pypi
jedi                      0.19.2                   pypi_0    pypi
jinja2                    3.1.4                    pypi_0    pypi
jiter                     0.5.0                    pypi_0    pypi
json5                     0.10.0                   pypi_0    pypi
jsonpointer               3.0.0                    pypi_0    pypi
jsonschema                4.23.0                   pypi_0    pypi
jsonschema-specifications 2023.12.1                pypi_0    pypi
jupyter                   1.1.1                    pypi_0    pypi
jupyter-client            8.6.3                    pypi_0    pypi
jupyter-console           6.6.3                    pypi_0    pypi
jupyter-core              5.7.2                    pypi_0    pypi
jupyter-events            0.10.0                   pypi_0    pypi
jupyter-lsp               2.2.5                    pypi_0    pypi
jupyter-server            2.14.2                   pypi_0    pypi
jupyter-server-terminals  0.5.3                    pypi_0    pypi
jupyterlab                4.3.2                    pypi_0    pypi
jupyterlab-pygments       0.3.0                    pypi_0    pypi
jupyterlab-server         2.27.3                   pypi_0    pypi
jupyterlab-widgets        3.0.13                   pypi_0    pypi
lark                      1.2.2                    pypi_0    pypi
ld_impl_linux-64          2.40                 h12ee557_0  
libffi                    3.4.4                h6a678d5_1  
libgcc-ng                 11.2.0               h1234567_1  
libgomp                   11.2.0               h1234567_1  
libstdcxx-ng              11.2.0               h1234567_1  
libuuid                   1.41.5               h5eee18b_0  
llvmlite                  0.43.0                   pypi_0    pypi
lm-format-enforcer        0.10.6                   pypi_0    pypi
markupsafe                2.1.5                    pypi_0    pypi
matplotlib-inline         0.1.7                    pypi_0    pypi
mistral-common            1.4.3                    pypi_0    pypi
mistune                   3.0.2                    pypi_0    pypi
mpmath                    1.3.0                    pypi_0    pypi
msgpack                   1.1.0                    pypi_0    pypi
msgspec                   0.18.6                   pypi_0    pypi
multidict                 6.1.0                    pypi_0    pypi
multiprocess              0.70.16                  pypi_0    pypi
nbclient                  0.10.1                   pypi_0    pypi
nbconvert                 7.16.4                   pypi_0    pypi
nbformat                  5.10.4                   pypi_0    pypi
ncurses                   6.4                  h6a678d5_0  
nest-asyncio              1.6.0                    pypi_0    pypi
networkx                  3.3                      pypi_0    pypi
notebook                  7.3.1                    pypi_0    pypi
notebook-shim             0.2.4                    pypi_0    pypi
numba                     0.60.0                   pypi_0    pypi
numpy                     1.26.4                   pypi_0    pypi
nvidia-cublas-cu12        12.1.3.1                 pypi_0    pypi
nvidia-cuda-cupti-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-nvrtc-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-runtime-cu12  12.1.105                 pypi_0    pypi
nvidia-cudnn-cu12         9.1.0.70                 pypi_0    pypi
nvidia-cufft-cu12         11.0.2.54                pypi_0    pypi
nvidia-curand-cu12        10.3.2.106               pypi_0    pypi
nvidia-cusolver-cu12      11.4.5.107               pypi_0    pypi
nvidia-cusparse-cu12      12.1.0.106               pypi_0    pypi
nvidia-ml-py              12.560.30                pypi_0    pypi
nvidia-nccl-cu12          2.20.5                   pypi_0    pypi
nvidia-nvjitlink-cu12     12.6.68                  pypi_0    pypi
nvidia-nvtx-cu12          12.1.105                 pypi_0    pypi
openai                    1.48.0                   pypi_0    pypi
openssl                   3.0.15               h5eee18b_0  
outlines                  0.0.46                   pypi_0    pypi
overrides                 7.7.0                    pypi_0    pypi
packaging                 24.1                     pypi_0    pypi
pandas                    2.2.3                    pypi_0    pypi
pandocfilters             1.5.1                    pypi_0    pypi
parso                     0.8.4                    pypi_0    pypi
partial-json-parser       0.2.1.1.post4            pypi_0    pypi
pexpect                   4.9.0                    pypi_0    pypi
pillow                    10.4.0                   pypi_0    pypi
pip                       24.2            py310h06a4308_0  
platformdirs              4.3.6                    pypi_0    pypi
plotly                    5.24.1                   pypi_0    pypi
prometheus-client         0.21.0                   pypi_0    pypi
prometheus-fastapi-instrumentator 7.0.0                    pypi_0    pypi
prompt-toolkit            3.0.48                   pypi_0    pypi
protobuf                  5.28.2                   pypi_0    pypi
psutil                    6.0.0                    pypi_0    pypi
ptyprocess                0.7.0                    pypi_0    pypi
pure-eval                 0.2.3                    pypi_0    pypi
py-cpuinfo                9.0.0                    pypi_0    pypi
pyairports                2.1.1                    pypi_0    pypi
pyarrow                   17.0.0                   pypi_0    pypi
pycountry                 24.6.1                   pypi_0    pypi
pycparser                 2.22                     pypi_0    pypi
pydantic                  2.9.2                    pypi_0    pypi
pydantic-core             2.23.4                   pypi_0    pypi
pygments                  2.18.0                   pypi_0    pypi
python                    3.10.14              h955ad1f_1  
python-dateutil           2.9.0.post0              pypi_0    pypi
python-dotenv             1.0.1                    pypi_0    pypi
python-json-logger        2.0.7                    pypi_0    pypi
pytz                      2024.2                   pypi_0    pypi
pyyaml                    6.0.2                    pypi_0    pypi
pyzmq                     26.2.0                   pypi_0    pypi
ray                       2.37.0                   pypi_0    pypi
readline                  8.2                  h5eee18b_0  
referencing               0.35.1                   pypi_0    pypi
regex                     2024.9.11                pypi_0    pypi
requests                  2.32.3                   pypi_0    pypi
rfc3339-validator         0.1.4                    pypi_0    pypi
rfc3986-validator         0.1.1                    pypi_0    pypi
rpds-py                   0.20.0                   pypi_0    pypi
safetensors               0.4.5                    pypi_0    pypi
send2trash                1.8.3                    pypi_0    pypi
sentencepiece             0.2.0                    pypi_0    pypi
setuptools                75.1.0          py310h06a4308_0  
six                       1.16.0                   pypi_0    pypi
sniffio                   1.3.1                    pypi_0    pypi
soupsieve                 2.6                      pypi_0    pypi
sqlite                    3.45.3               h5eee18b_0  
stack-data                0.6.3                    pypi_0    pypi
stanza                    1.9.2                    pypi_0    pypi
starlette                 0.38.6                   pypi_0    pypi
sympy                     1.13.3                   pypi_0    pypi
tenacity                  9.0.0                    pypi_0    pypi
terminado                 0.18.1                   pypi_0    pypi
tiktoken                  0.7.0                    pypi_0    pypi
timm                      1.0.12                   pypi_0    pypi
tinycss2                  1.4.0                    pypi_0    pypi
tk                        8.6.14               h39e8969_0  
tokenizers                0.20.0                   pypi_0    pypi
tomli                     2.2.1                    pypi_0    pypi
torch                     2.4.0                    pypi_0    pypi
torchvision               0.19.0                   pypi_0    pypi
tornado                   6.4.2                    pypi_0    pypi
tqdm                      4.66.5                   pypi_0    pypi
traitlets                 5.14.3                   pypi_0    pypi
transformers              4.45.0                   pypi_0    pypi
triton                    3.0.0                    pypi_0    pypi
types-python-dateutil     2.9.0.20241003           pypi_0    pypi
typing-extensions         4.12.2                   pypi_0    pypi
tzdata                    2024.2                   pypi_0    pypi
uri-template              1.3.0                    pypi_0    pypi
urllib3                   2.2.3                    pypi_0    pypi
uvicorn                   0.30.6                   pypi_0    pypi
uvloop                    0.20.0                   pypi_0    pypi
vllm                      0.6.2                    pypi_0    pypi
watchfiles                0.24.0                   pypi_0    pypi
wcwidth                   0.2.13                   pypi_0    pypi
webcolors                 24.11.1                  pypi_0    pypi
webencodings              0.5.1                    pypi_0    pypi
websocket-client          1.8.0                    pypi_0    pypi
websockets                13.1                     pypi_0    pypi
wheel                     0.44.0          py310h06a4308_0  
widgetsnbextension        4.0.13                   pypi_0    pypi
xformers                  0.0.27.post2             pypi_0    pypi
xxhash                    3.5.0                    pypi_0    pypi
xz                        5.4.6                h5eee18b_1  
yarl                      1.12.1                   pypi_0    pypi
zipp                      3.20.2                   pypi_0    pypi
zlib                      1.2.13               h5eee18b_1  
Package                           Version
--------------------------------- --------------
accelerate                        1.1.1
aiohappyeyeballs                  2.4.0
aiohttp                           3.10.6
aiosignal                         1.3.1
annotated-types                   0.7.0
anthropic                         0.40.0
anyio                             4.6.0
argon2-cffi                       23.1.0
argon2-cffi-bindings              21.2.0
arrow                             1.3.0
asttokens                         3.0.0
async-lru                         2.0.4
async-timeout                     4.0.3
attrs                             24.2.0
babel                             2.16.0
beautifulsoup4                    4.12.3
bleach                            6.2.0
certifi                           2024.8.30
cffi                              1.17.1
charset-normalizer                3.3.2
click                             8.1.7
cloudpickle                       3.0.0
comm                              0.2.2
datasets                          3.0.1
debugpy                           1.8.9
decorator                         5.1.1
defusedxml                        0.7.1
dill                              0.3.8
diskcache                         5.6.3
distro                            1.9.0
einops                            0.8.0
emoji                             2.14.0
exceptiongroup                    1.2.2
executing                         2.1.0
fastapi                           0.115.0
fastjsonschema                    2.21.1
filelock                          3.16.1
fqdn                              1.5.1
frozenlist                        1.4.1
fsspec                            2024.6.1
gguf                              0.10.0
h11                               0.14.0
httpcore                          1.0.5
httptools                         0.6.1
httpx                             0.27.2
huggingface-hub                   0.25.1
idna                              3.10
importlib_metadata                8.5.0
interegular                       0.3.3
ipykernel                         6.29.5
ipython                           8.30.0
ipywidgets                        8.1.5
isoduration                       20.11.0
jedi                              0.19.2
Jinja2                            3.1.4
jiter                             0.5.0
json5                             0.10.0
jsonpointer                       3.0.0
jsonschema                        4.23.0
jsonschema-specifications         2023.12.1
jupyter                           1.1.1
jupyter_client                    8.6.3
jupyter-console                   6.6.3
jupyter_core                      5.7.2
jupyter-events                    0.10.0
jupyter-lsp                       2.2.5
jupyter_server                    2.14.2
jupyter_server_terminals          0.5.3
jupyterlab                        4.3.2
jupyterlab_pygments               0.3.0
jupyterlab_server                 2.27.3
jupyterlab_widgets                3.0.13
lark                              1.2.2
llvmlite                          0.43.0
lm-format-enforcer                0.10.6
MarkupSafe                        2.1.5
matplotlib-inline                 0.1.7
mistral_common                    1.4.3
mistune                           3.0.2
mpmath                            1.3.0
msgpack                           1.1.0
msgspec                           0.18.6
multidict                         6.1.0
multiprocess                      0.70.16
nbclient                          0.10.1
nbconvert                         7.16.4
nbformat                          5.10.4
nest-asyncio                      1.6.0
networkx                          3.3
notebook                          7.3.1
notebook_shim                     0.2.4
numba                             0.60.0
numpy                             1.26.4
nvidia-cublas-cu12                12.1.3.1
nvidia-cuda-cupti-cu12            12.1.105
nvidia-cuda-nvrtc-cu12            12.1.105
nvidia-cuda-runtime-cu12          12.1.105
nvidia-cudnn-cu12                 9.1.0.70
nvidia-cufft-cu12                 11.0.2.54
nvidia-curand-cu12                10.3.2.106
nvidia-cusolver-cu12              11.4.5.107
nvidia-cusparse-cu12              12.1.0.106
nvidia-ml-py                      12.560.30
nvidia-nccl-cu12                  2.20.5
nvidia-nvjitlink-cu12             12.6.68
nvidia-nvtx-cu12                  12.1.105
openai                            1.48.0
outlines                          0.0.46
overrides                         7.7.0
packaging                         24.1
pandas                            2.2.3
pandocfilters                     1.5.1
parso                             0.8.4
partial-json-parser               0.2.1.1.post4
pexpect                           4.9.0
pillow                            10.4.0
pip                               24.2
platformdirs                      4.3.6
plotly                            5.24.1
prometheus_client                 0.21.0
prometheus-fastapi-instrumentator 7.0.0
prompt_toolkit                    3.0.48
protobuf                          5.28.2
psutil                            6.0.0
ptyprocess                        0.7.0
pure_eval                         0.2.3
py-cpuinfo                        9.0.0
pyairports                        2.1.1
pyarrow                           17.0.0
pycountry                         24.6.1
pycparser                         2.22
pydantic                          2.9.2
pydantic_core                     2.23.4
Pygments                          2.18.0
python-dateutil                   2.9.0.post0
python-dotenv                     1.0.1
python-json-logger                2.0.7
pytz                              2024.2
PyYAML                            6.0.2
pyzmq                             26.2.0
ray                               2.37.0
referencing                       0.35.1
regex                             2024.9.11
requests                          2.32.3
rfc3339-validator                 0.1.4
rfc3986-validator                 0.1.1
rpds-py                           0.20.0
safetensors                       0.4.5
Send2Trash                        1.8.3
sentencepiece                     0.2.0
setuptools                        75.1.0
six                               1.16.0
sniffio                           1.3.1
soupsieve                         2.6
stack-data                        0.6.3
stanza                            1.9.2
starlette                         0.38.6
sympy                             1.13.3
tenacity                          9.0.0
terminado                         0.18.1
tiktoken                          0.7.0
timm                              1.0.12
tinycss2                          1.4.0
tokenizers                        0.20.0
tomli                             2.2.1
torch                             2.4.0
torchvision                       0.19.0
tornado                           6.4.2
tqdm                              4.66.5
traitlets                         5.14.3
transformers                      4.45.0
triton                            3.0.0
types-python-dateutil             2.9.0.20241003
typing_extensions                 4.12.2
tzdata                            2024.2
uri-template                      1.3.0
urllib3                           2.2.3
uvicorn                           0.30.6
uvloop                            0.20.0
vllm                              0.6.2
watchfiles                        0.24.0
wcwidth                           0.2.13
webcolors                         24.11.1
webencodings                      0.5.1
websocket-client                  1.8.0
websockets                        13.1
wheel                             0.44.0
widgetsnbextension                4.0.13
xformers                          0.0.27.post2
xxhash                            3.5.0
yarl                              1.12.1
zipp                              3.20.2

Currently Loaded Modules:
  1) eth_proxy      3) gcc/12.2.0      5) r/4.3.2       7) python/3.11.6   9) nccl/2.18.3-1    11) python_cuda/3.11.6
  2) julia/1.10.3   4) stack/2024-06   6) hdf5/1.14.3   8) cuda/12.1.1    10) openblas/0.3.24

 

Testing Slurm Variables...
SLURM_JOB_USER=gcardenal
SLURM_TASKS_PER_NODE=1
SLURM_JOB_UID=608619
SLURM_TASK_PID=3453822
SLURM_JOB_GPUS=5,7
SLURM_LOCALID=0
SLURM_SUBMIT_DIR=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation
SLURMD_NODENAME=eu-ts-01
SLURM_JOB_START_TIME=1737121875
SLURM_CLUSTER_NAME=euler-24-production
SLURM_JOB_END_TIME=1737136275
SLURM_CPUS_ON_NODE=8
SLURM_JOB_CPUS_PER_NODE=8
SLURM_GPUS_ON_NODE=2
SLURM_GTIDS=0
SLURM_JOB_PARTITION=gpupr.4h
SLURM_TRES_PER_TASK=cpu=8
SLURM_JOB_NUM_NODES=1
SLURM_JOBID=21073161
SLURM_GPUS=nvidia_a100_80gb_pcie:2
SLURM_JOB_QOS=es_ilic/gpupr/4
SLURM_PROCID=0
SLURM_CPUS_PER_TASK=8
SLURM_NTASKS=1
SLURM_TOPOLOGY_ADDR=.euler_a100_80_lca_ib.eu-ts-01
SLURM_TOPOLOGY_ADDR_PATTERN=switch.switch.node
SLURM_MEM_PER_CPU=10240
SLURM_SCRIPT_CONTEXT=prolog_task
SLURM_NODELIST=eu-ts-01
SLURM_JOB_ACCOUNT=gpupr/es_ilic
SLURM_PRIO_PROCESS=0
SLURM_NPROCS=1
SLURM_NNODES=1
SLURM_SUBMIT_HOST=eu-g5-030-1
SLURM_JOB_ID=21073161
SLURM_NODEID=0
SLURM_CONF=/cluster/slurm/adm/etc/slurm.conf
SLURM_JOB_NAME=llama_no_api
SLURM_JOB_GID=492010
SLURM_JOB_NODELIST=eu-ts-01
Fri Jan 17 14:51:29 2025       
+-----------------------------------------------------------------------------------------+
| NVIDIA-SMI 550.127.08             Driver Version: 550.127.08     CUDA Version: 12.4     |
|-----------------------------------------+------------------------+----------------------+
| GPU  Name                 Persistence-M | Bus-Id          Disp.A | Volatile Uncorr. ECC |
| Fan  Temp   Perf          Pwr:Usage/Cap |           Memory-Usage | GPU-Util  Compute M. |
|                                         |                        |               MIG M. |
|=========================================+========================+======================|
|   0  NVIDIA A100 80GB PCIe          On  |   00000000:84:00.0 Off |                    0 |
| N/A   51C    P0             49W /  300W |       1MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
|   1  NVIDIA A100 80GB PCIe          On  |   00000000:E4:00.0 Off |                    0 |
| N/A   54C    P0             51W /  300W |       1MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
                                                                                         
+-----------------------------------------------------------------------------------------+
| Processes:                                                                              |
|  GPU   GI   CI        PID   Type   Process name                              GPU Memory |
|        ID   ID                                                               Usage      |
|=========================================================================================|
|  No running processes found                                                             |
+-----------------------------------------------------------------------------------------+
Node IP: 10.205.9.17
JobId=21073161 JobName=llama_no_api
   UserId=gcardenal(608619) GroupId=gcardenal-group(492010) MCS_label=N/A
   Priority=5807 Nice=0 Account=gpupr/es_ilic QOS=es_ilic/gpupr/4
   JobState=RUNNING Reason=None Dependency=(null)
   Requeue=0 Restarts=0 BatchFlag=1 Reboot=0 ExitCode=0:0
   RunTime=00:00:15 TimeLimit=04:00:00 TimeMin=N/A
   SubmitTime=2025-01-17T14:47:27 EligibleTime=2025-01-17T14:47:27
   AccrueTime=2025-01-17T14:47:27
   StartTime=2025-01-17T14:51:15 EndTime=2025-01-17T18:51:15 Deadline=N/A
   SuspendTime=None SecsPreSuspend=0 LastSchedEval=2025-01-17T14:51:15 Scheduler=Main
   Partition=gpupr.4h AllocNode:Sid=eu-g5-030-1:27237
   ReqNodeList=(null) ExcNodeList=(null)
   NodeList=eu-ts-01
   BatchHost=eu-ts-01
   NumNodes=1 NumCPUs=8 NumTasks=1 CPUs/Task=8 ReqB:S:C:T=0:0:*:*
   ReqTRES=cpu=8,mem=80G,node=1,billing=347340,gres/gpu=2,gres/gpu:nvidia_a100_80gb_pcie=2,gres/gpumem=85899345920
   AllocTRES=cpu=8,mem=80G,node=1,billing=347340,gres/gpu=2,gres/gpu:nvidia_a100_80gb_pcie=2,gres/gpumem=0
   Socks/Node=* NtasksPerN:B:S:C=0:0:*:1 CoreSpec=*
   MinCPUsNode=8 MinMemoryCPU=10G MinTmpDiskNode=0
   Features=(null) DelayBoot=00:00:00
   OverSubscribe=OK Contiguous=0 Licenses=(null) Network=(null)
   Command=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/generate_answers.sh
   WorkDir=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation
   StdErr=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/llama_no_api21073161.out
   StdIn=/dev/null
   StdOut=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/llama_no_api21073161.out
   TresPerJob=gres/gpu:nvidia_a100_80gb_pcie:2
   TresPerNode=gres/gpumem:80G
   TresPerTask=cpu=8
   

Running in standalone mode...
I0117 14:51:33.880000 22589460875072 torch/distributed/run.py:859] 
I0117 14:51:33.880000 22589460875072 torch/distributed/run.py:859] **************************************
I0117 14:51:33.880000 22589460875072 torch/distributed/run.py:859] Rendezvous info:
I0117 14:51:33.880000 22589460875072 torch/distributed/run.py:859] --rdzv-backend=c10d --rdzv-endpoint=localhost:0 --rdzv-id=3066a789-4a78-4e38-813a-aac56271091d
I0117 14:51:33.880000 22589460875072 torch/distributed/run.py:859] **************************************
I0117 14:51:33.880000 22589460875072 torch/distributed/run.py:859] 
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188] Starting elastic_operator with launch configs:
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   entrypoint       : get_model_answers_and_prompt_generation.py
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   min_nodes        : 1
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   max_nodes        : 1
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   nproc_per_node   : 1
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   run_id           : 3066a789-4a78-4e38-813a-aac56271091d
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   rdzv_backend     : c10d
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   rdzv_endpoint    : localhost:0
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   rdzv_configs     : {'timeout': 900}
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   max_restarts     : 0
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   monitor_interval : 5
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   log_dir          : /scratch/tmp.21073161.gcardenal/torchelastic_182ipzan
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188]   metrics_cfg      : {}
I0117 14:51:33.881000 22589460875072 torch/distributed/launcher/api.py:188] 
I0117 14:51:33.889000 22589460875072 torch/distributed/elastic/agent/server/api.py:866] [default] starting workers for entrypoint: python3
I0117 14:51:33.889000 22589460875072 torch/distributed/elastic/agent/server/api.py:699] [default] Rendezvous'ing worker group
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568] [default] Rendezvous complete for workers. Result:
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   restart_count=0
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   master_addr=eu-ts-01.euler.ethz.ch
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   master_port=43717
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   group_rank=0
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   group_world_size=1
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   local_ranks=[0]
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   role_ranks=[0]
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   global_ranks=[0]
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   role_world_sizes=[1]
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568]   global_world_sizes=[1]
I0117 14:51:34.089000 22589460875072 torch/distributed/elastic/agent/server/api.py:568] 
I0117 14:51:34.090000 22589460875072 torch/distributed/elastic/agent/server/api.py:707] [default] Starting worker group
I0117 14:51:34.090000 22589460875072 torch/distributed/elastic/agent/server/local_elastic_agent.py:168] Environment variable 'TORCHELASTIC_ENABLE_FILE_TIMER' not found. Do not start FileTimerServer.
I0117 14:51:34.091000 22589460875072 torch/distributed/elastic/multiprocessing/api.py:263] log directory set to: /scratch/tmp.21073161.gcardenal/torchelastic_182ipzan/3066a789-4a78-4e38-813a-aac56271091d_h0_bg2op
I0117 14:51:34.091000 22589460875072 torch/distributed/elastic/multiprocessing/api.py:358] Setting worker0 reply file to: /scratch/tmp.21073161.gcardenal/torchelastic_182ipzan/3066a789-4a78-4e38-813a-aac56271091d_h0_bg2op/attempt_0/0/error.json
2025-01-17 14:51:40.490836: I tensorflow/core/util/port.cc:113] oneDNN custom operations are on. You may see slightly different numerical results due to floating-point round-off errors from different computation orders. To turn them off, set the environment variable `TF_ENABLE_ONEDNN_OPTS=0`.
2025-01-17 14:51:40.528739: E external/local_xla/xla/stream_executor/cuda/cuda_dnn.cc:9261] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered
2025-01-17 14:51:40.528802: E external/local_xla/xla/stream_executor/cuda/cuda_fft.cc:607] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered
2025-01-17 14:51:40.530309: E external/local_xla/xla/stream_executor/cuda/cuda_blas.cc:1515] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered
2025-01-17 14:51:40.537104: I tensorflow/core/platform/cpu_feature_guard.cc:182] This TensorFlow binary is optimized to use available CPU instructions in performance-critical operations.
To enable the following instructions: AVX2 AVX512F AVX512_VNNI AVX512_BF16 FMA, in other operations, rebuild TensorFlow with the appropriate compiler flags.
2025-01-17 14:51:42.157633: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Could not find TensorRT
API call for Llama failed with error: Connection error.
Falling back to local Llama inference - Loading model...
Loading checkpoint shards:   0%|                                                                        | 0/30 [00:00<?, ?it/s]Loading checkpoint shards:   3%|██▏                                                             | 1/30 [00:13<06:44, 13.93s/it]Loading checkpoint shards:   7%|████▎                                                           | 2/30 [00:58<14:47, 31.68s/it]Loading checkpoint shards:  10%|██████▍                                                         | 3/30 [01:34<15:18, 34.01s/it]Loading checkpoint shards:  13%|████████▌                                                       | 4/30 [01:43<10:28, 24.17s/it]Loading checkpoint shards:  17%|██████████▋                                                     | 5/30 [02:28<13:12, 31.71s/it]Loading checkpoint shards:  20%|████████████▊                                                   | 6/30 [02:44<10:29, 26.23s/it]Loading checkpoint shards:  23%|██████████████▉                                                 | 7/30 [02:51<07:37, 19.89s/it]Loading checkpoint shards:  27%|█████████████████                                               | 8/30 [03:00<06:05, 16.60s/it]Loading checkpoint shards:  30%|███████████████████▏                                            | 9/30 [03:10<05:03, 14.43s/it]Loading checkpoint shards:  33%|█████████████████████                                          | 10/30 [03:18<04:08, 12.42s/it]Loading checkpoint shards:  37%|███████████████████████                                        | 11/30 [03:35<04:22, 13.82s/it]Loading checkpoint shards:  40%|█████████████████████████▏                                     | 12/30 [03:43<03:36, 12.01s/it]Loading checkpoint shards:  43%|███████████████████████████▎                                   | 13/30 [03:57<03:34, 12.60s/it]Loading checkpoint shards:  47%|█████████████████████████████▍                                 | 14/30 [04:13<03:39, 13.69s/it]Loading checkpoint shards:  50%|███████████████████████████████▌                               | 15/30 [04:36<04:08, 16.59s/it]Loading checkpoint shards:  53%|█████████████████████████████████▌                             | 16/30 [04:41<03:02, 13.05s/it]Loading checkpoint shards:  57%|███████████████████████████████████▋                           | 17/30 [04:47<02:20, 10.77s/it]Loading checkpoint shards:  60%|█████████████████████████████████████▊                         | 18/30 [05:25<03:47, 18.99s/it]Loading checkpoint shards:  63%|███████████████████████████████████████▉                       | 19/30 [05:39<03:14, 17.69s/it]Loading checkpoint shards:  67%|██████████████████████████████████████████                     | 20/30 [05:45<02:21, 14.10s/it]Loading checkpoint shards:  70%|████████████████████████████████████████████                   | 21/30 [05:51<01:43, 11.54s/it]Loading checkpoint shards:  73%|██████████████████████████████████████████████▏                | 22/30 [05:55<01:15,  9.42s/it]Loading checkpoint shards:  77%|████████████████████████████████████████████████▎              | 23/30 [06:24<01:46, 15.17s/it]Loading checkpoint shards:  80%|██████████████████████████████████████████████████▍            | 24/30 [06:29<01:13, 12.20s/it]Loading checkpoint shards:  83%|████████████████████████████████████████████████████▌          | 25/30 [06:40<00:58, 11.76s/it]Loading checkpoint shards:  87%|██████████████████████████████████████████████████████▌        | 26/30 [06:48<00:43, 10.79s/it]Loading checkpoint shards:  90%|████████████████████████████████████████████████████████▋      | 27/30 [06:54<00:28,  9.36s/it]Loading checkpoint shards:  93%|██████████████████████████████████████████████████████████▊    | 28/30 [07:12<00:23, 11.78s/it]Loading checkpoint shards:  97%|████████████████████████████████████████████████████████████▉  | 29/30 [08:18<00:28, 28.16s/it]Loading checkpoint shards: 100%|███████████████████████████████████████████████████████████████| 30/30 [08:21<00:00, 20.66s/it]Loading checkpoint shards: 100%|███████████████████████████████████████████████████████████████| 30/30 [08:21<00:00, 16.73s/it]
Starting inference for question locally (Llama): How is HIV diagnosed?
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

How is HIV diagnosed?<|eot_id|>assistant

HIV (Human Immunodeficiency Virus) diagnosis involves a combination of medical history, physical examination, and laboratory tests. Here's an overview of the diagnostic process:

**Initial Screening:**

1. **Risk assessment**: A healthcare provider will ask questions about your medical history, sexual behavior, and other risk factors to determine if you're at risk for HIV.
2. **Physical examination**: A physical exam may be performed to look for signs of HIV-related illnesses or infections.

**Laboratory Tests:**

1. **Rapid tests**: These are point-of-care tests that can provide quick results (usually within 20-30 minutes). They detect the presence of HIV antibodies or antigens in the blood or oral fluid.
2. **Enzyme-linked immunosorbent assay (ELISA)**: This is a laboratory-based test that detects HIV antibodies in the blood. If the result is positive, it's usually confirmed with a follow-up test.
3. **Western blot test**: This test is used to confirm a positive ELISA result. It detects the presence of specific HIV proteins (antigens) in the blood.
4. **Nucleic acid-based tests (NATs)**: These tests detect the genetic material (RNA or DNA) of the virus in the blood. They're often used to diagnose HIV in infants born to HIV-positive mothers or in people with early infection.
5. **CD4 cell count**: This test measures the number of CD4 T cells (a type of immune cell) in the blood. A low CD4 count can indicate HIV infection.
6. **Viral load test**: This test measures the amount of HIV in the blood. It's used to monitor the effectiveness of treatment and detect any changes in the virus.

**Testing Algorithm:**

1. **Initial test**: A rapid test or ELISA is performed.
2. **Confirmatory test**: If the initial test is positive, a Western blot test or NAT is performed to confirm the diagnosis.
3. **Additional tests**: CD4 cell count, viral load test, and other tests may be performed to assess the stage of infection and guide treatment.

**Window Period:**

The window period is the time between exposure to HIV and when the test can detect the virus. The window period varies depending on the test:

* Rapid tests: 23-90 days
* ELISA: 23-90 days
* Western blot: 23-90 days
* NATs: 10-33 days

It's essential to note that HIV testing is not 100% accurate, and false-negative results can occur, especially during the window period. If you've been exposed to HIV, it's crucial to get tested and follow up with your healthcare provider for confirmation and guidance.

**Who should get tested?**

The Centers for Disease Control and Prevention (CDC) recommends that the following groups get tested for HIV:

* All adults aged 18-64 years
* Pregnant women
* People with high-risk behaviors (e.g., unprotected sex, injection drug use)
* People with symptoms of HIV infection
* People who have been diagnosed with another sexually transmitted infection (STI)

Remember, early diagnosis and treatment can significantly improve the quality of life for people living with HIV. If you're concerned about your risk or have questions, consult with a healthcare provider or a local health clinic.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What are the different stages of HIV?
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

What are the different stages of HIV?<|eot_id|>assistant

HIV (Human Immunodeficiency Virus) infection progresses through several stages, which can vary in duration and severity from person to person. The stages of HIV infection are:

**Stage 1: Acute HIV Infection (0-6 weeks)**

* This is the initial stage of HIV infection, which occurs when the virus first enters the body.
* During this stage, the virus replicates rapidly, and the person may experience flu-like symptoms, such as fever, headache, and fatigue.
* The body's immune system responds to the infection, and the virus is shed in large quantities, making the person highly infectious.

**Stage 2: Clinical Latency (6 weeks to 10 years or more)**

* After the acute stage, the virus enters a latent phase, during which the immune system is able to control the virus, and the person may not experience any symptoms.
* The virus is still present in the body, but it is not actively replicating at high levels.
* This stage can last for many years, and some people may not even know they are infected.

**Stage 3: Symptomatic HIV Infection (10 years or more)**

* As the virus continues to replicate, the immune system begins to weaken, and the person may start to experience symptoms, such as:
	+ Weight loss
	+ Fatigue
	+ Swollen lymph nodes
	+ Skin rashes
	+ Oral thrush
	+ Diarrhea
* The virus is now actively replicating, and the person is more likely to transmit the infection to others.

**Stage 4: AIDS (Acquired Immune Deficiency Syndrome)**

* This is the most advanced stage of HIV infection, which occurs when the immune system is severely weakened, and the person is susceptible to opportunistic infections and certain types of cancer.
* AIDS is defined by the presence of one or more opportunistic infections, such as:
	+ Pneumocystis pneumonia (PCP)
	+ Kaposi's sarcoma
	+ Toxoplasmosis
	+ Cryptococcosis
* Without treatment, AIDS can lead to serious illness and death.

**Undetectable Viral Load**

* With effective antiretroviral therapy (ART), people living with HIV can achieve an undetectable viral load, which means that the virus is suppressed to very low levels, and the person is much less likely to transmit the infection to others.
* This stage is not a cure, but it is a significant milestone in managing the infection and preventing transmission.

It's essential to note that with proper treatment and care, people living with HIV can manage the infection and prevent progression to AIDS. Early diagnosis, treatment, and adherence to ART can significantly improve the quality of life and life expectancy for individuals living with HIV.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How is HIV transmitted?
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

How is HIV transmitted?<|eot_id|>assistant

HIV (Human Immunodeficiency Virus) is transmitted through certain bodily fluids from a person who has a detectable viral load and is not taking antiretroviral therapy (ART) or is not virally suppressed. The primary modes of HIV transmission are:

1. **Unprotected sex**: HIV can be transmitted through vaginal, anal, or oral sex without using a condom or other barrier methods. The risk of transmission is higher for anal sex and lower for oral sex.
2. **Sharing needles or syringes**: Sharing needles or syringes to inject drugs can spread HIV if the equipment is contaminated with infected blood.
3. **Mother-to-child transmission**: HIV can be passed from a pregnant woman to her child during pregnancy, childbirth, or breastfeeding. However, with proper treatment and care, the risk of mother-to-child transmission can be significantly reduced.
4. **Blood transfusions**: Although rare, HIV can be transmitted through blood transfusions if the blood is not properly screened for the virus.
5. **Occupational exposure**: Healthcare workers may be at risk of HIV transmission through needlestick injuries or other exposure to infected bodily fluids.

It's essential to note that HIV is not transmitted through:

* Casual contact, such as hugging, shaking hands, or sharing food and drinks
* Air or water
* Insect bites
* Saliva, sweat, or tears, unless these fluids are mixed with blood
* Toilet seats, doorknobs, or other surfaces

To reduce the risk of HIV transmission, it's crucial to:

* Practice safe sex using condoms or other barrier methods
* Use sterile needles and syringes
* Get tested for HIV regularly
* Take antiretroviral therapy (ART) if diagnosed with HIV
* Follow safe injection practices
* Avoid sharing personal care items, such as razors or toothbrushes

Remember, HIV is a manageable condition with proper treatment and care. If you have concerns about HIV transmission or would like to get tested, consult a healthcare professional or a local health organization for guidance and support.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What comorbidities are common among people living 
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

What comorbidities are common among people living with HIV?<|eot_id|>assistant

People living with HIV (PLWH) are at increased risk for various comorbidities, which are health conditions that occur simultaneously with HIV. These comorbidities can be related to the direct effects of HIV infection, antiretroviral therapy (ART), or lifestyle factors. Here are some common comorbidities among PLWH:

1. **Mental health disorders**: Depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders are common among PLWH.
2. **Cardiovascular disease**: PLWH are at higher risk for cardiovascular disease, including heart attacks, strokes, and peripheral artery disease, due to chronic inflammation and antiretroviral therapy.
3. **Liver disease**: Co-infection with hepatitis B or C viruses, as well as antiretroviral therapy, can increase the risk of liver disease, including liver fibrosis and cirrhosis.
4. **Kidney disease**: HIV-associated nephropathy, a type of kidney disease, can occur in PLWH, especially those with advanced HIV disease or those taking certain antiretroviral medications.
5. **Osteoporosis**: PLWH are at higher risk for osteoporosis, which can increase the risk of fractures, due to chronic inflammation, antiretroviral therapy, and hormonal changes.
6. **Cancer**: PLWH are at higher risk for certain types of cancer, including:
	* Kaposi's sarcoma
	* Non-Hodgkin lymphoma
	* Cervical cancer
	* Anal cancer
	* Lung cancer
7. **Neurological disorders**: PLWH are at higher risk for neurological disorders, including:
	* HIV-associated neurocognitive disorder (HAND)
	* Seizures
	* Stroke
	* Peripheral neuropathy
8. **Metabolic disorders**: PLWH are at higher risk for metabolic disorders, including:
	* Insulin resistance and type 2 diabetes
	* Dyslipidemia (high cholesterol and triglycerides)
	* Lipodystrophy (abnormal fat distribution)
9. **Gastrointestinal disorders**: PLWH are at higher risk for gastrointestinal disorders, including:
	* Gastroesophageal reflux disease (GERD)
	* Peptic ulcers
	* Diarrhea
	* Malabsorption
10. **Infectious diseases**: PLWH are at higher risk for other infectious diseases, including:
	* Tuberculosis (TB)
	* Pneumocystis jirovecii pneumonia (PCP)
	* Toxoplasmosis
	* Cryptococcal meningitis

It's essential for PLWH to work closely with their healthcare providers to manage these comorbidities and prevent complications. Regular health check-ups, screenings, and adherence to antiretroviral therapy can help mitigate the risks associated with these comorbidities.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How can HIV be prevented?
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

How can HIV be prevented?<|eot_id|>assistant

HIV (Human Immunodeficiency Virus) can be prevented through a combination of strategies that reduce the risk of transmission. Here are some effective ways to prevent HIV:

1. **Practice safe sex**: Use condoms consistently and correctly during vaginal, anal, and oral sex. Condoms can reduce the risk of HIV transmission by up to 70-80%.
2. **Use pre-exposure prophylaxis (PrEP)**: PrEP is a daily medication that can reduce the risk of HIV infection by up to 92% if taken as prescribed. It is recommended for individuals who are at high risk of HIV infection, such as those with multiple sex partners or those who inject drugs.
3. **Use post-exposure prophylaxis (PEP)**: PEP is an emergency medication that can prevent HIV infection if taken within 72 hours of exposure. It is recommended for individuals who have had unprotected sex or shared needles with someone who is HIV-positive.
4. **Get tested and know your status**: Knowing your HIV status is crucial in preventing transmission. Get tested regularly, especially if you have multiple sex partners or engage in high-risk behaviors.
5. **Use clean needles and equipment**: If you inject drugs, use clean needles and equipment to reduce the risk of HIV transmission.
6. **Avoid sharing personal items**: Avoid sharing personal items such as razors, toothbrushes, or nail clippers, as they can potentially transmit HIV through blood or other bodily fluids.
7. **Get vaccinated against other STIs**: Getting vaccinated against other sexually transmitted infections (STIs) such as hepatitis B and human papillomavirus (HPV) can reduce the risk of HIV transmission.
8. **Practice monogamy**: Having a monogamous relationship with a partner who is HIV-negative can reduce the risk of HIV transmission.
9. **Use condoms with sex toys**: Use condoms with sex toys to reduce the risk of HIV transmission.
10. **Educate yourself and others**: Educate yourself and others about HIV prevention, transmission, and treatment to reduce stigma and promote safe behaviors.

Additionally, there are several other strategies that can help prevent HIV transmission, including:

* **Male circumcision**: Male circumcision has been shown to reduce the risk of HIV transmission by up to 60%.
* **HIV treatment as prevention**: Antiretroviral therapy (ART) can reduce the viral load of HIV-positive individuals, making them less likely to transmit the virus to others.
* **HIV self-testing**: HIV self-testing can increase testing rates and reduce the risk of transmission by allowing individuals to know their status and take preventive measures.

Remember, prevention is key in reducing the spread of HIV. By practicing safe behaviors and taking preventive measures, you can reduce your risk of HIV transmission and protect yourself and others.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How frequently ART must be taken?
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

How frequently ART must be taken?<|eot_id|>assistant

Antiretroviral therapy (ART) is typically taken daily, and the exact frequency depends on the specific medication regimen prescribed by a healthcare provider. Most ART regimens involve taking a combination of medications, usually in the form of one or more pills, once or twice a day.

Here are some general guidelines on the frequency of ART:

1. **Once-daily regimens**: Many modern ART regimens are designed to be taken once a day, often in the morning or evening. Examples include single-tablet regimens like Atripla (efavirenz/emtricitabine/tenofovir), Complera (rilpivirine/emtricitabine/tenofovir), and Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir).
2. **Twice-daily regimens**: Some ART regimens require taking medications twice a day, usually in the morning and evening. Examples include regimens that include medications like lamivudine, zidovudine, or abacavir.
3. **Fixed-dose combinations**: Some medications, like Truvada (emtricitabine/tenofovir) or Epzicom (abacavir/lamivudine), are taken once daily, but may need to be taken with other medications that have a different dosing schedule.

It's essential to follow the specific dosing instructions provided by your healthcare provider, as taking ART as prescribed is crucial for:

* Maintaining viral suppression
* Preventing drug resistance
* Minimizing side effects
* Achieving optimal treatment outcomes

If you have any questions or concerns about your ART regimen or dosing schedule, be sure to discuss them with your healthcare provider.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How can we prevent Perinatal transmission of HIV?
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

How can we prevent Perinatal transmission of HIV?<|eot_id|>assistant

Preventing perinatal transmission of HIV (mother-to-child transmission) is crucial to reduce the risk of HIV infection in newborns. Here are the ways to prevent perinatal transmission of HIV:

1. **HIV testing and counseling**: All pregnant women should be tested for HIV as part of routine prenatal care. If a woman is found to be HIV-positive, she should receive counseling and support to reduce the risk of transmission to her baby.
2. **Antiretroviral therapy (ART)**: HIV-positive pregnant women should start ART as soon as possible to suppress the virus and reduce the risk of transmission to their baby. The goal is to achieve an undetectable viral load.
3. **Combination antiretroviral therapy**: Combination ART, which includes a combination of three or more antiretroviral medications, is more effective in preventing perinatal transmission than monotherapy.
4. **Elective cesarean delivery**: For women with a high viral load (above 1000 copies/mL) near the time of delivery, elective cesarean delivery can reduce the risk of transmission.
5. **Avoid breastfeeding**: HIV-positive mothers should avoid breastfeeding their babies, as HIV can be transmitted through breast milk. Formula feeding is recommended instead.
6. **Antiretroviral prophylaxis for the newborn**: Newborns born to HIV-positive mothers should receive antiretroviral prophylaxis, usually with zidovudine (AZT) or nevirapine, to reduce the risk of transmission.
7. **Post-exposure prophylaxis (PEP)**: If a baby is born to an HIV-positive mother and did not receive antiretroviral prophylaxis during pregnancy or delivery, PEP can be given to the baby within 72 hours of birth to reduce the risk of transmission.
8. **Pre-conception care**: For women with HIV who are planning to become pregnant, pre-conception care can help optimize their health and reduce the risk of transmission to their baby.
9. **Male partner involvement**: Involving male partners in HIV testing and counseling can help reduce the risk of transmission and promote a supportive environment for the pregnant woman.
10. **Healthcare provider education and training**: Healthcare providers should be educated and trained on the latest guidelines and best practices for preventing perinatal transmission of HIV.

By implementing these measures, the risk of perinatal transmission of HIV can be significantly reduced, and the number of children born with HIV can be decreased.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What are the main cell types infected with HIV?
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

What are the main cell types infected with HIV?<|eot_id|>assistant

The main cell types infected with HIV (Human Immunodeficiency Virus) are:

1. **CD4+ T cells** (also known as T helper cells): These cells play a crucial role in the immune system, helping to coordinate the response to infections. HIV infects and destroys CD4+ T cells, which can lead to a weakened immune system and increased susceptibility to opportunistic infections.
2. **Macrophages**: These cells are a type of white blood cell that engulfs and digests foreign particles and microorganisms. Macrophages can become infected with HIV and serve as a reservoir for the virus.
3. **Dendritic cells**: These cells are responsible for presenting antigens to T cells, helping to trigger an immune response. Dendritic cells can also become infected with HIV and contribute to the spread of the virus.
4. **Lymphocytes** (including B cells and natural killer cells): While not as susceptible to infection as CD4+ T cells, other types of lymphocytes can also become infected with HIV.

These cell types are all part of the immune system, and HIV's ability to infect and destroy them is a key aspect of its pathogenesis. The virus uses the CD4 receptor on the surface of these cells to gain entry and replicate, ultimately leading to the depletion of CD4+ T cells and the development of acquired immunodeficiency syndrome (AIDS).
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What is the difference between HIV and AIDS?
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

What is the difference between HIV and AIDS?<|eot_id|>assistant

HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) are two related but distinct conditions.

**HIV:**

HIV is a viral infection that attacks the body's immune system, specifically the CD4 cells (also known as T cells), which help the immune system fight off infections. If left untreated, HIV can progress and damage the immune system, making it harder for the body to fight off infections and diseases.

HIV is typically spread through:

* Unprotected sex with an infected person
* Sharing needles or syringes with an infected person
* Mother-to-child transmission during pregnancy, childbirth, or breastfeeding
* Blood transfusions (although this is rare in countries with strict blood screening)

**AIDS:**

AIDS is the most advanced stage of HIV infection. It occurs when the immune system is severely damaged, and the body is unable to fight off opportunistic infections and diseases. AIDS is characterized by a CD4 cell count below 200 cells per cubic millimeter of blood (normal range is 500-1600 cells/mm³) and/or the presence of one or more opportunistic infections, such as:

* Pneumocystis pneumonia (PCP)
* Kaposi's sarcoma
* Toxoplasmosis
* Cryptococcosis

AIDS is a life-threatening condition that can lead to serious illnesses and death if left untreated.

**Key differences:**

1. **Infection vs. disease**: HIV is the virus that causes the infection, while AIDS is the disease that results from the advanced stage of the infection.
2. **Immune system damage**: HIV damages the immune system, while AIDS is the result of severe immune system damage.
3. **Symptoms**: HIV may not have noticeable symptoms, while AIDS is characterized by severe symptoms, such as weight loss, diarrhea, and opportunistic infections.
4. **Treatment**: HIV can be managed with antiretroviral therapy (ART), which can prevent the progression to AIDS. AIDS, on the other hand, requires more aggressive treatment and management of opportunistic infections.

In summary, HIV is the virus that can lead to AIDS, which is the most advanced stage of the infection, characterized by severe immune system damage and life-threatening opportunistic infections.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How is HIV not transmitted?
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

How is HIV not transmitted?<|eot_id|>assistant

HIV (Human Immunodeficiency Virus) is not transmitted through the following ways:

1. **Casual contact**: Shaking hands, hugging, kissing, or sharing food and drinks with someone who has HIV does not transmit the virus.
2. **Air or water**: HIV is not transmitted through the air, water, or by breathing the same air as someone with HIV.
3. **Insect bites**: Mosquitoes, ticks, and other insects do not transmit HIV.
4. **Saliva, sweat, or tears**: HIV is not transmitted through saliva, sweat, or tears, unless these fluids are mixed with blood and come into contact with a mucous membrane or an open wound.
5. **Toilet seats or public facilities**: HIV is not transmitted through contact with toilet seats, doorknobs, or other public facilities.
6. **Food handling**: HIV is not transmitted through food handling, even if the person preparing the food has HIV.
7. **Sharing personal items**: Sharing personal items like towels, razors, or toothbrushes does not transmit HIV, unless these items are contaminated with blood.
8. **Coughing or sneezing**: HIV is not transmitted through coughing or sneezing, even if the person with HIV has a cold or flu.
9. **Touching or holding**: Touching or holding someone with HIV does not transmit the virus.
10. **Donating blood**: In the United States, all donated blood is screened for HIV, and the risk of transmitting HIV through blood transfusion is extremely low.

It's essential to remember that HIV is primarily transmitted through:

* Unprotected sex (vaginal, anal, or oral) with someone who has HIV
* Sharing needles or syringes with someone who has HIV
* Mother-to-child transmission during pregnancy, childbirth, or breastfeeding (if the mother is not receiving effective treatment)

If you have concerns about HIV transmission or would like to know more about prevention and testing, consult a healthcare professional or a trusted resource, such as the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO).
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What is known about the switch that occurs between
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

What is known about the switch that occurs between patients with latent HIV and active infection?<|eot_id|>assistant

The switch from latent HIV infection to active infection is a complex and not fully understood process. However, research has shed some light on the key factors and mechanisms involved. Here's a summary of what is currently known:

**Latent HIV infection:**
Latent HIV infection, also known as viral latency, is a state where the virus is present in the body but not actively replicating. During latency, the virus integrates into the host cell's genome and remains dormant, with minimal or no viral transcription. This state is characterized by low or undetectable levels of viral RNA and proteins.

**Triggers for reactivation:**
Several factors can trigger the reactivation of latent HIV, leading to active infection. These include:

1. **Immune activation**: Activation of the immune system, such as during infections, inflammation, or vaccination, can stimulate latent HIV to reactivate.
2. **Cellular stress**: Stress signals, like those triggered by DNA damage or oxidative stress, can also reactivate latent HIV.
3. **Epigenetic changes**: Epigenetic modifications, such as histone modifications or DNA methylation, can influence the expression of latent HIV genes.
4. **Hormonal changes**: Hormonal fluctuations, like those experienced during pregnancy or menopause, may also contribute to HIV reactivation.
5. **Antigen presentation**: The presentation of viral antigens to the immune system can stimulate latent HIV to reactivate.

**Mechanisms of reactivation:**
The reactivation of latent HIV involves the interplay of multiple cellular and molecular mechanisms, including:

1. **NF-κB signaling**: The NF-κB transcription factor plays a crucial role in the reactivation of latent HIV by binding to specific DNA sequences and inducing the expression of viral genes.
2. **Histone modifications**: Histone acetylation and other chromatin modifications can relax the chromatin structure, allowing for the transcription of latent HIV genes.
3. **Transcriptional activators**: Proteins like Tat and other transcriptional activators can bind to the HIV promoter and enhance the expression of viral genes.
4. **Cellular cofactors**: Cellular proteins, such as cyclin T1 and CDK9, can interact with the HIV Tat protein to facilitate viral transcription.

**Consequences of reactivation:**
The reactivation of latent HIV can lead to:

1. **Viral replication**: The production of new viral particles, which can infect other cells and contribute to the progression of HIV disease.
2. **Immune activation**: The reactivation of latent HIV can stimulate an immune response, leading to the activation of immune cells and the production of pro-inflammatory cytokines.
3. **Tissue damage**: The reactivation of latent HIV can cause damage to tissues, particularly in the gut-associated lymphoid tissue (GALT), which is a major reservoir for latent HIV.

**Current research and implications:**
Understanding the mechanisms of latent HIV reactivation is crucial for the development of effective therapies aimed at curing HIV. Researchers are exploring various strategies to:

1. **Reactivate latent HIV**: To make the virus vulnerable to antiretroviral therapy or immune clearance.
2. **Block reactivation**: To prevent the reactivation of latent HIV and maintain viral suppression.
3. **Target latent reservoirs**: To develop therapies that can specifically target and eliminate latent HIV reservoirs.

While significant progress has been made, the complex interplay between latent HIV and the host immune system remains an area of active research, and a deeper understanding of the underlying mechanisms is needed to develop effective strategies for HIV cure and remission.
Saved Llama answers (category=1, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/Llama_cluster/Llama_answers_category_1.1_HIV_EQ.json
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 58-year-old woman with HIV infection is brought 
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/μL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?<|eot_id|>assistant

Based on the clinical presentation, laboratory results, and imaging findings, the most likely diagnosis is Primary Central Nervous System Lymphoma (PCNSL).

Here's why:

1. **Clinical presentation**: The patient's symptoms, such as headaches, blurred vision, confusion, ataxia, and memory impairment, are consistent with a brain lesion.
2. **HIV infection and low CD4+ count**: Patients with HIV/AIDS are at increased risk of developing PCNSL, especially when their CD4+ count is low (< 100/μL).
3. **Cerebrospinal fluid analysis**: Lymphocytic predominant pleocytosis (increased lymphocytes in the cerebrospinal fluid) and the presence of Epstein-Barr virus (EBV) DNA by PCR are consistent with PCNSL. EBV is associated with PCNSL in immunocompromised patients, including those with HIV/AIDS.
4. **Imaging findings**: The MRI shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. This is a characteristic appearance of PCNSL, which often presents as a single lesion in the deep brain structures, such as the basal ganglia, thalamus, or corpus callosum.
5. **Exclusion of other diagnoses**: The patient's symptoms and laboratory results are less consistent with other diagnoses, such as toxoplasmosis (which is more common in HIV patients with a low CD4+ count, but typically presents with multiple ring-enhancing lesions) or progressive multifocal leukoencephalopathy (PML, which typically presents with multiple white matter lesions and does not typically show enhancement on MRI).

Overall, the combination of clinical, laboratory, and imaging findings points towards Primary Central Nervous System Lymphoma (PCNSL) as the most likely diagnosis in this patient.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 25-year-old sexually active male presents to an 
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?<|eot_id|>assistant

The medication that acts on the gp41 subunit of the HIV envelope glycoprotein is Enfuvirtide (T-20), also known as Fuzeon. However, this is not typically a first-line treatment and is usually reserved for salvage therapy or in combination with other medications.

A more commonly prescribed medication that targets the HIV envelope glycoprotein is Maraviroc, but it acts on the CCR5 co-receptor, not the gp41 subunit.

The correct answer is Enfuvirtide (T-20), which is an HIV fusion inhibitor that binds to the gp41 subunit of the HIV envelope glycoprotein, preventing the fusion of the viral envelope with the host cell membrane.

It's worth noting that the initial treatment for HIV typically involves a combination of medications, often including two nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent, which can be a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or an integrase strand transfer inhibitor (INSTI). The choice of medication depends on various factors, including the patient's viral load, CD4 count, and any potential resistance or intolerance to certain medications.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A mother with HIV has given birth to a healthy boy
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A mother with HIV has given birth to a healthy boy 2 days ago. She takes her antiretroviral medication regularly and is compliant with the therapy. Before being discharged, her doctor explains that she cannot breastfeed the child since there is a risk of infection through breastfeeding and stresses that the child can benefit from formula feeding. The physician stresses the importance of not overheating the formula since Vitamin C may be inactivated by overheating. What molecular process could be impaired if the mother boiled the formula longer than needed?<|eot_id|>assistant

If the mother boiled the formula longer than needed, the molecular process that could be impaired is denaturation of proteins and degradation of vitamins, particularly Vitamin C (ascorbic acid). However, the most relevant process related to Vitamin C is the breakdown of its molecular structure due to heat.

Vitamin C is a heat-labile and water-soluble vitamin. When formula is overheated, the Vitamin C molecules can undergo hydrolysis and oxidation reactions, leading to the formation of inactive compounds. This process is an example of thermal degradation.

In more detail, the thermal degradation of Vitamin C involves the breakdown of its molecular structure, which is sensitive to heat, water, and oxygen. When Vitamin C is exposed to high temperatures, the molecule can undergo a series of reactions, including:

1. Hydrolysis: Water molecules (H2O) can break the Vitamin C molecule, leading to the formation of inactive compounds.
2. Oxidation: Oxygen molecules (O2) can react with Vitamin C, leading to the formation of oxidized products, such as dehydroascorbic acid, which is inactive.

As a result of these reactions, the Vitamin C content in the formula can be significantly reduced, impairing its nutritional value and potential health benefits for the infant.

It's essential for the mother to follow the physician's advice and prepare the formula according to the manufacturer's instructions to minimize the risk of overheating and preserve the nutritional value of the formula, including Vitamin C.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 35-year-old woman presents to a physician’s offi
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 35-year-old woman presents to a physician’s office for a follow-up visit. She recently underwent a complete physical examination with routine laboratory tests. She also had a Pap smear and testing for sexually transmitted diseases. Since her divorce 2 years ago, she had sexual encounters with random men at bars or social events and frequently did not use any form of protection during sexual intercourse. She was shown to be positive for the human immunodeficiency virus (HIV). Combination anti-retroviral treatment is initiated including zidovudine, didanosine, and efavirenz. One week later, she is rushed to the hospital where she is diagnosed with acute pancreatitis. What precautions in her medication will be required after pancreatitis resolves with treatment?<|eot_id|>assistant

The patient in this scenario is diagnosed with acute pancreatitis after starting combination antiretroviral therapy (cART) for HIV, which includes zidovudine, didanosine, and efavirenz. The development of acute pancreatitis in this context is most likely related to the use of didanosine, as it is known to have a side effect of causing pancreatitis.

Given this situation, once the pancreatitis resolves with treatment, precautions in her medication will be required to prevent recurrence. The primary precaution would be to **discontinue the use of didanosine**. Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) that has been associated with an increased risk of pancreatitis, a potentially life-threatening condition. By removing didanosine from her regimen, the risk of recurrent pancreatitis is significantly reduced.

The patient's antiretroviral regimen would need to be adjusted to replace didanosine with an alternative NRTI or another class of antiretroviral drugs that does not carry the same risk of pancreatitis. The choice of new medication would depend on various factors, including the patient's viral load, CD4 count, resistance testing results, and potential side effects of other medications.

Zidovudine and efavirenz, the other components of her initial regimen, are not typically associated with pancreatitis to the same extent as didanosine. Therefore, these medications could potentially be continued, assuming there are no other contraindications or adverse effects.

In summary, the key precaution after pancreatitis resolves would be to **modify the antiretroviral regimen by discontinuing didanosine and replacing it with a suitable alternative**, to minimize the risk of recurrent pancreatitis while maintaining effective control of HIV infection.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A physician scientist is looking for a more effici
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?<|eot_id|>assistant

The most likely target of the antibody the physician scientist is designing is the HIV envelope protein gp120 or gp41, which are part of the Env complex.

The Env complex, composed of gp120 and gp41, is the primary target of the humoral immune response to HIV. gp120 is responsible for binding to the CD4 receptor on host cells, while gp41 is involved in the fusion of the viral envelope with the host cell membrane. These proteins are highly immunogenic and are the primary targets of neutralizing antibodies produced by the host in response to HIV infection.

The ELISA and western blot assays used to diagnose HIV infection typically detect antibodies against these envelope proteins, specifically gp120 and gp41. Therefore, it is likely that the physician scientist is designing an antibody that targets one or both of these proteins, with the goal of generating a more potent and effective antibody-based therapy against HIV.

It's worth noting that gp120 is a more common target for antibody-based therapies, as it is more accessible to antibodies and has a more complex structure that can be targeted by multiple epitopes. However, gp41 is also an important target, and some antibodies that target gp41 have been shown to be highly effective in neutralizing HIV.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 50-year-old HIV-positive male presents to the ER
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?<|eot_id|>assistant

Based on the clinical presentation and biopsy findings, the most likely causal organism is Aspergillus.

Here's the reasoning:

1. **HIV-positive status**: Patients with HIV/AIDS are immunocompromised and more susceptible to opportunistic infections, including fungal infections like aspergillosis.
2. **Fever and hemoptysis**: These symptoms are consistent with a pulmonary infection, and the presence of hemoptysis (coughing up blood) suggests that the infection is causing damage to the lung tissue.
3. **Fibrocavitary lesion on chest radiograph**: This type of lesion is characteristic of a chronic pulmonary infection, and aspergillosis is a common cause of such lesions in immunocompromised patients.
4. **Septate hyphae that branch at acute angles on biopsy**: This is a hallmark feature of Aspergillus species. The septate hyphae (hyphae with septa, or divisions) that branch at acute angles (typically 45-degree angles) are characteristic of Aspergillus, distinguishing it from other types of fungi.

Aspergillus is a common opportunistic pathogen that can cause a range of diseases, including pulmonary aspergillosis, in immunocompromised individuals. The patient's HIV-positive status and the clinical and radiographic findings make Aspergillus the most likely causal organism in this case.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 43-year-old man with HIV infection comes to the 
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3–4 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?<|eot_id|>assistant

The addition of valganciclovir to the patient's current medication regimen, which includes zidovudine, lamivudine, and dolutegravir, puts the patient at greatest risk for hematologic adverse effects, particularly **neutropenia** and **anemia**.

Valganciclovir is a nucleoside analogue that can cause bone marrow suppression, leading to decreased production of blood cells, including neutrophils (neutropenia) and red blood cells (anemia). Zidovudine, a component of the patient's antiretroviral therapy, is also known to cause bone marrow suppression, particularly neutropenia and anemia. The concurrent use of valganciclovir and zidovudine may increase the risk of these hematologic adverse effects due to their overlapping toxicities.

Therefore, the patient should be closely monitored for signs of neutropenia (e.g., fever, infection) and anemia (e.g., fatigue, weakness, pallor), and his complete blood count (CBC) should be regularly checked to assess the risk of these adverse effects.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 28-year-old G1P0 woman at 16 weeks estimated ges
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient’s concern?<|eot_id|>assistant

For a newborn born to an HIV-positive mother, the most appropriate diagnostic test to detect HIV infection in the baby would be the HIV DNA PCR (Polymerase Chain Reaction) test, also known as the HIV viral DNA test. This test detects the genetic material of the virus itself, rather than the antibodies produced by the baby's immune system in response to the virus.

The HIV DNA PCR test is the preferred test for diagnosing HIV infection in infants because:

1. **Early detection**: It can detect HIV infection as early as 1-2 weeks after birth, allowing for early initiation of antiretroviral therapy (ART) if the baby is infected.
2. **High sensitivity and specificity**: The test is highly sensitive and specific, reducing the risk of false-negative or false-positive results.
3. **Detection of viral DNA**: The test detects the viral DNA, which is a direct indicator of HIV infection, rather than relying on the detection of antibodies, which can be present due to maternal transmission.

Other tests, such as the HIV antibody test, are not suitable for diagnosing HIV infection in newborns because:

1. **Maternal antibody transfer**: Newborns may have maternal HIV antibodies, which can be transferred from the mother during pregnancy or breastfeeding, making it difficult to distinguish between maternal and infant antibodies.
2. **False-positive results**: The HIV antibody test can produce false-positive results in newborns due to the presence of maternal antibodies.

The American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC) recommend that all infants born to HIV-positive mothers undergo HIV DNA PCR testing at 14-21 days of age, with repeat testing at 1-2 months and 4-6 months of age to confirm the diagnosis.

In this scenario, the HIV DNA PCR test would be the most appropriate diagnostic test to address the patient's concern about the possible transmission of HIV to her baby.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 32-year-old man comes to the office for a routin
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?<|eot_id|>assistant

This is a complex and sensitive situation, requiring careful consideration of ethical and legal obligations. The physician has a duty to maintain patient confidentiality, but also has a responsibility to protect the health and well-being of others, including the patient's wife.

In this scenario, the most appropriate next step by the physician would be to:

1. **Counsel the patient on the importance of disclosure**: The physician should explain to the patient the risks of not disclosing his HIV status to his wife, including the potential for transmission and the importance of her getting tested and seeking medical care if necessary.
2. **Encourage the patient to disclose to his wife**: The physician should encourage the patient to disclose his HIV status to his wife, emphasizing the importance of honesty and transparency in their relationship, as well as the need to protect her health.
3. **Offer to facilitate disclosure or provide resources**: If the patient is unwilling or unable to disclose to his wife, the physician could offer to facilitate the disclosure process or provide resources and support to help the patient do so.
4. **Consider reporting to public health authorities**: Depending on the jurisdiction, the physician may be required to report the patient's HIV diagnosis to public health authorities, who can then contact the patient's partners and offer testing and counseling. This can help prevent further transmission and ensure that those at risk receive necessary medical care.
5. **Respect patient confidentiality, but not at the expense of others' health**: While the physician has a duty to maintain patient confidentiality, this duty is not absolute. If the physician believes that the patient's wife is at significant risk of harm and the patient is unwilling to disclose, the physician may need to take steps to protect her health, such as reporting the situation to public health authorities or seeking a court order to disclose the information.

It's essential to note that the specific laws and regulations regarding HIV disclosure and reporting vary by jurisdiction, and the physician should be familiar with the relevant laws and guidelines in their area.

In terms of the American Medical Association (AMA) and Centers for Disease Control and Prevention (CDC) guidelines, they recommend that:

* Physicians should encourage patients with HIV to disclose their status to their sexual partners.
* Physicians should provide patients with information and resources to facilitate disclosure.
* Physicians should report HIV cases to public health authorities, as required by law.
* Physicians should respect patient confidentiality, but not at the expense of others' health.

Ultimately, the physician's primary responsibility is to protect the health and well-being of all patients, including the patient's wife, while also respecting the patient's autonomy and confidentiality.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 41-year-old HIV-positive male presents to the ER
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 41-year-old HIV-positive male presents to the ER with a 4-day history of headaches and nuchal rigidity. A lumbar puncture shows an increase in CSF protein and a decrease in CSF glucose. When stained with India ink, light microscopy of the patient’s CSF reveals encapsulated yeast with narrow-based buds. Assuming a single pathogenic organism is responsible for this patient’s symptoms, what diagnostic test results would also be expected in this patient?<|eot_id|>assistant

Based on the patient's symptoms and the results of the lumbar puncture, the most likely diagnosis is cryptococcal meningitis, caused by the encapsulated yeast Cryptococcus neoformans.

The diagnostic test results that would also be expected in this patient include:

1. **Positive Cryptococcal Antigen (CRAG) test**: This is a latex agglutination test that detects the presence of cryptococcal capsular antigen in the CSF or serum. It is a rapid and sensitive test that can confirm the diagnosis of cryptococcal meningitis.
2. **Positive culture of CSF for Cryptococcus neoformans**: The CSF sample can be cultured on a suitable medium, such as Sabouraud agar, to isolate and identify the yeast.
3. **Elevated CSF opening pressure**: Cryptococcal meningitis can cause increased intracranial pressure, which can be measured during the lumbar puncture procedure.
4. **Abnormal CSF lactate and pH levels**: The CSF lactate level may be elevated, and the pH may be decreased, indicating impaired CSF glucose metabolism and lactic acid production by the yeast.
5. **CD4 count < 100 cells/μL**: As an HIV-positive patient, the CD4 count is an important indicator of immune function. A low CD4 count increases the risk of opportunistic infections like cryptococcal meningitis.

These test results, in combination with the clinical presentation and the microscopic findings of encapsulated yeast with narrow-based buds, would confirm the diagnosis of cryptococcal meningitis in this patient.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama):  What would be the best methodological approach to
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

What would be the best methodological approach to study microRNAs as therapeutic targets in HIV patients?<|eot_id|>assistant

Studying microRNAs (miRNAs) as therapeutic targets in HIV patients requires a comprehensive and multi-disciplinary approach. Here's a suggested methodological framework:

**Research Design:**

1. **Literature Review**: Conduct a thorough review of existing literature on miRNAs, HIV, and their interactions to identify potential miRNA targets and their roles in HIV pathogenesis.
2. **Hypothesis Generation**: Formulate hypotheses based on the literature review, focusing on specific miRNAs and their potential therapeutic applications in HIV patients.
3. **Study Design**: Design a study to investigate the expression and function of selected miRNAs in HIV patients, using a combination of in vitro, in vivo, and clinical approaches.

**In Vitro Studies:**

1. **Cell Culture Models**: Use HIV-infected cell lines (e.g., T cells, macrophages) to study miRNA expression, regulation, and function.
2. **miRNA Profiling**: Perform miRNA microarray or next-generation sequencing (NGS) to identify differentially expressed miRNAs in HIV-infected cells.
3. **Functional Assays**: Use techniques like luciferase reporter assays, Western blotting, and qRT-PCR to validate the function of selected miRNAs in HIV replication, immune response, and cellular processes.

**In Vivo Studies:**

1. **Animal Models**: Use HIV-infected animal models (e.g., humanized mice, non-human primates) to study the role of miRNAs in HIV pathogenesis and treatment.
2. **miRNA Delivery**: Use viral vectors (e.g., lentivirus, adenovirus) or non-viral methods (e.g., nanoparticles, liposomes) to deliver miRNA mimics or inhibitors to target tissues.
3. **Pharmacokinetics and Pharmacodynamics**: Evaluate the biodistribution, stability, and efficacy of miRNA-based therapeutics in vivo.

**Clinical Studies:**

1. **Patient Recruitment**: Recruit HIV patients with well-characterized clinical profiles and collect blood samples for miRNA analysis.
2. **miRNA Profiling**: Perform miRNA profiling in patient samples to identify correlations between miRNA expression and clinical outcomes (e.g., viral load, CD4+ T cell count).
3. **Longitudinal Studies**: Conduct longitudinal studies to monitor changes in miRNA expression and clinical outcomes in response to antiretroviral therapy (ART) or other treatments.

**Bioinformatics and Computational Analysis:**

1. **miRNA Target Prediction**: Use computational tools (e.g., TargetScan, miRBase) to predict miRNA targets and their potential roles in HIV pathogenesis.
2. **Network Analysis**: Construct and analyze miRNA-regulatory networks to identify key miRNAs and their interactions with other molecules.
3. **Machine Learning**: Apply machine learning algorithms to integrate miRNA expression data with clinical and demographic variables to predict treatment outcomes and identify potential biomarkers.

**Validation and Translation:**

1. **Validation**: Validate the results of in vitro and in vivo studies using independent datasets and experimental approaches.
2. **Translation**: Translate the findings into clinical applications, such as developing miRNA-based therapeutics or diagnostic tools.
3. **Collaboration**: Collaborate with clinicians, industry partners, and regulatory agencies to advance the development of miRNA-based treatments for HIV patients.

By following this methodological framework, researchers can comprehensively investigate miRNAs as therapeutic targets in HIV patients and contribute to the development of innovative treatments for this complex and multifaceted disease.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What is known about DNA methylation profiles in pa
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?<|eot_id|>assistant

DNA methylation plays a crucial role in the regulation of gene expression, and its profiles have been extensively studied in the context of HIV-1 infection. Here's a summary of what is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection:

**Latent HIV-1 infection:**

1. **Hypermethylation of HIV-1 promoter**: In latently infected cells, the HIV-1 promoter is often hypermethylated, which silences viral transcription and contributes to the latent state.
2. **Methylation of host genes**: Latent HIV-1 infection is also associated with changes in the methylation of host genes involved in immune response, cell cycle regulation, and apoptosis.
3. **Epigenetic silencing of viral genes**: DNA methylation, along with other epigenetic mechanisms, contributes to the silencing of viral genes, preventing viral replication and maintaining latency.

**Active HIV-1 infection:**

1. **Hypomethylation of HIV-1 promoter**: In actively infected cells, the HIV-1 promoter is often hypomethylated, allowing for active viral transcription and replication.
2. **Methylation of host genes**: Active HIV-1 infection is associated with changes in the methylation of host genes involved in immune response, cell signaling, and cellular metabolism.
3. **Epigenetic reprogramming**: HIV-1 infection can lead to epigenetic reprogramming of host cells, including changes in DNA methylation, histone modifications, and chromatin structure, which can contribute to the development of viral persistence and pathogenesis.

**Comparison of DNA methylation profiles between latent and active HIV-1 infection:**

1. **Divergent methylation patterns**: DNA methylation profiles differ significantly between latently and actively infected cells, with latent cells exhibiting more pronounced methylation of the HIV-1 promoter and host genes involved in immune response.
2. **Methylation signatures**: Specific methylation signatures have been identified that distinguish latent from active HIV-1 infection, which could potentially be used as biomarkers for disease monitoring and treatment response.

**Clinical implications:**

1. **Latency reversal**: Understanding the epigenetic mechanisms underlying HIV-1 latency is crucial for the development of latency-reversing therapies, which aim to reactivate latent viruses and eliminate them with antiretroviral therapy.
2. **Biomarkers for disease monitoring**: DNA methylation profiles could serve as biomarkers for monitoring disease progression, treatment response, and the presence of latent reservoirs.
3. **Therapeutic targets**: Epigenetic regulators, including DNA methyltransferases and demethylases, may be targeted to modulate HIV-1 gene expression and promote viral clearance.

In summary, DNA methylation profiles differ significantly between latent and active HIV-1 infection, with latent cells exhibiting more pronounced methylation of the HIV-1 promoter and host genes involved in immune response. Understanding these epigenetic mechanisms is essential for the development of effective therapies to target latent HIV-1 reservoirs and ultimately achieve a cure for HIV-1 infection.
Saved Llama answers (category=3, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/Llama_cluster/Llama_answers_category_3.1_HIV_EQ.json
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 26-year-old female with AIDS (CD4 count: 47) pre
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 26-year-old female with AIDS (CD4 count: 47) presents to the emergency department in severe pain. She states that over the past week she has been fatigued and has had a progressively worse headache and fever. These symptoms have failed to remit leading her to seek care in the ED. A lumbar puncture is performed which demonstrates an opening pressure of 285 mm H2O, increased lymphocytes, elevated protein, and decreased glucose. The emergency physician subsequently initiates treatment with IV amphotericin B and PO flucytosine. What additional treatment in the acute setting may be warranted in this patient?<|eot_id|>assistant

Based on the patient's symptoms and laboratory results, it is likely that she has cryptococcal meningitis, a common opportunistic infection in patients with AIDS. The elevated opening pressure, increased lymphocytes, elevated protein, and decreased glucose in the cerebrospinal fluid (CSF) are consistent with this diagnosis.

In addition to the treatment initiated with IV amphotericin B and PO flucytosine, which is the standard treatment for cryptococcal meningitis, the patient may also benefit from the following additional treatment in the acute setting:

1. **Serial lumbar punctures**: To relieve elevated intracranial pressure (ICP) and prevent complications such as vision loss or brain herniation. The patient's opening pressure is significantly elevated at 285 mm H2O, which is a concern for increased ICP.
2. **Corticosteroids**: Some guidelines recommend the use of corticosteroids, such as dexamethasone, to reduce inflammation and swelling in the brain, although this is not universally recommended.
3. **Anticonvulsant prophylaxis**: To prevent seizures, which can occur in patients with cryptococcal meningitis.
4. **Supportive care**: Including pain management, antipyretics, and hydration to manage symptoms and prevent complications.
5. **Monitoring for adverse effects**: Close monitoring for adverse effects of amphotericin B, such as nephrotoxicity, and flucytosine, such as bone marrow suppression.

It is essential to note that the management of cryptococcal meningitis requires a multidisciplinary approach, and the patient should be admitted to the hospital for close monitoring and treatment.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): You are reviewing raw data from a research study p
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

You are reviewing raw data from a research study performed at your medical center examining the effectiveness of a novel AIDS screening examination. The study enrolled 250 patients with confirmed AIDS, and 240 of these patients demonstrated a positive screening examination. The control arm of the study enrolled 250 patients who do not have AIDS, and only 5 of these patients tested positive on the novel screening examination. What is the NPV of this novel test?<|eot_id|>assistant

To calculate the Negative Predictive Value (NPV) of the novel AIDS screening examination, we first need to understand what NPV is. The NPV of a test is the probability that a person with a negative test result truly does not have the disease. It is calculated using the formula:

NPV = True Negatives / (True Negatives + False Negatives)

From the information provided:

- True Negatives (TN) are the patients without AIDS who tested negative. Since 5 out of 250 patients without AIDS tested positive, 250 - 5 = 245 patients without AIDS tested negative.
- False Negatives (FN) are the patients with AIDS who tested negative. Since 240 out of 250 patients with AIDS tested positive, 250 - 240 = 10 patients with AIDS tested negative.

Plugging the values into the NPV formula:

NPV = TN / (TN + FN) = 245 / (245 + 10)

NPV = 245 / 255

NPV = 0.9608 or approximately 96.08%

Therefore, the Negative Predictive Value of this novel AIDS screening examination is approximately 96.08%. This means that if a patient tests negative using this screening test, there is a 96.08% probability that the patient truly does not have AIDS.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 46-year-old Caucasian male with past medical his
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 46-year-old Caucasian male with past medical history of HIV (CD4: 77/mm^3), hypertension, hyperlipidemia, and osteoarthritis presents to the emergency department with sudden weakness of his right hand. He reports that the weakness has gradually been getting worse and that this morning he dropped his cup of coffee. He has never had anything like this happen to him before, although he was hospitalized last year for pneumonia. He reports inconsistent adherence to his home medications, which include raltegravir, tenofovir, emtricitabine, TMP-SMX, hydrochlorothiazide, pravastatin, and occasional ibuprofen. His father died of a myocardial infarction at the age of 60, and his mother suffered a stroke at the age of 72. The patient's temperature is 102.6°F (39.2°C), blood pressure is 156/92 mmHg, pulse is 88/min, and respirations are 18/min. On neurological exam, he has 3/5 strength in the distal muscles of the right extremity with preserved sensation. His neurological exam is normal in all other extremities. What is the next best step in management for this patient?<|eot_id|>assistant

Given the patient's presentation of sudden weakness in one extremity, fever, and a history of HIV with a low CD4 count, the clinical suspicion for an opportunistic infection or a stroke is high. The patient's inconsistent adherence to his antiretroviral therapy (ART) regimen increases his risk for opportunistic infections and potentially for immune reconstitution inflammatory syndrome (IRIS) if he were to restart his medications. The patient's symptoms of focal weakness, particularly with 3/5 strength in the distal muscles of the right extremity and preserved sensation, suggest a possible central nervous system (CNS) process such as a stroke or an opportunistic CNS infection (e.g., toxoplasmosis, CNS lymphoma, progressive multifocal leukoencephalopathy).

The next best step in management for this patient would be to urgently perform neuroimaging to evaluate for potential causes of his focal neurological deficit. Given the acute onset of symptoms, a non-contrast computed tomography (CT) scan of the head would be the initial imaging modality of choice to quickly rule out a hemorrhagic stroke. However, given the patient's HIV status and the possibility of an opportunistic infection, magnetic resonance imaging (MRI) of the brain with and without contrast would provide more detailed information and is preferred if available promptly. MRI can better evaluate for ischemic stroke, infections, and masses, including those associated with HIV such as toxoplasmosis or primary CNS lymphoma.

Additionally, while awaiting imaging results, the following steps should be considered:
1. **Laboratory tests**: Complete blood count (CBC), electrolyte panel, liver function tests, and a CD4 count (if not recently checked) to assess the current immune status.
2. **Blood cultures**: To evaluate for potential bacteremia, especially given the fever.
3. **Lumbar puncture (LP)**: If the imaging does not show a mass effect or increased intracranial pressure, an LP can be performed to evaluate for CNS infections (e.g., cryptococcal meningitis, toxoplasmosis, viral encephalitis).
4. **Restart ART**: If the patient has been off his ART, restarting it should be considered, but ideally after consulting with an HIV specialist, especially given the potential for IRIS.
5. **Stroke protocol**: If a stroke is suspected, the patient should be evaluated by a neurologist, and thrombolytic therapy or other acute stroke management strategies should be considered based on the timing and nature of the stroke.

Given the complexity of this patient's presentation, consultation with neurology, infectious disease, and possibly HIV specialist services would be beneficial to guide further management.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 44-year-old man is brought to the emergency depa
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 44-year-old man is brought to the emergency department by his daughter for a 1-week history of right leg weakness, unsteady gait, and multiple falls. During the past 6 months, he has become more forgetful and has sometimes lost his way along familiar routes. He has been having difficulties operating simple kitchen appliances such as the dishwasher and the coffee maker. He has recently become increasingly paranoid, agitated, and restless. He has HIV, hypertension, and type 2 diabetes mellitus. His last visit to a physician was more than 2 years ago, and he has been noncompliant with his medications. His temperature is 37.2 °C (99.0 °F), blood pressure is 152/68 mm Hg, pulse is 98/min, and respirations are 14/min. He is somnolent and slightly confused. He is oriented to person, but not place or time. There is mild lymphadenopathy in the cervical, axillary, and inguinal areas. Neurological examination shows right lower extremity weakness with normal tone and no other focal deficits. Laboratory studies show: Hemoglobin 9.2 g/dL, Leukocyte count 3600/mm3, Platelet count 140,000/mm3, CD4+ count 56/μL, HIV viral load > 100,000 copies/mL, Serum: Cryptococcal antigen negative, Toxoplasma gondii IgG positive. An MRI of the brain shows disseminated, nonenhancing white matter lesions with no mass effect. What is the most likely diagnosis?<|eot_id|>assistant

Based on the patient's symptoms, laboratory results, and imaging findings, the most likely diagnosis is Progressive Multifocal Leukoencephalopathy (PML).

Here's why:

1. **Clinical presentation**: The patient has a subacute onset of neurological symptoms, including right leg weakness, unsteady gait, and cognitive decline (forgetfulness, difficulty with daily tasks, and disorientation). These symptoms are consistent with a progressive neurological disorder.
2. **Immunocompromised state**: The patient has advanced HIV disease, as indicated by a low CD4+ count (56/μL) and a high viral load (> 100,000 copies/mL). This immunocompromised state increases the risk of opportunistic infections and neurological disorders.
3. **MRI findings**: The MRI shows disseminated, nonenhancing white matter lesions without mass effect, which is characteristic of PML. PML is a demyelinating disease caused by the JC virus, which is a common virus that can reactivate in immunocompromised individuals.
4. **Laboratory results**: The patient's laboratory results, including a low CD4+ count, high viral load, and positive Toxoplasma gondii IgG (indicating past exposure), are consistent with advanced HIV disease. The negative cryptococcal antigen test helps to rule out cryptococcal meningitis, another opportunistic infection that can cause neurological symptoms in HIV-infected individuals.
5. **Exclusion of other diagnoses**: While the patient's symptoms and laboratory results could suggest other diagnoses, such as toxoplasmosis or primary CNS lymphoma, the MRI findings and clinical presentation are more consistent with PML.

PML is a rare and often fatal disease that requires prompt diagnosis and treatment. The patient's noncompliance with antiretroviral therapy (ART) and lack of recent medical follow-up have likely contributed to the progression of his HIV disease and the development of PML. Initiating ART and considering other treatments, such as plasma exchange or immunomodulatory therapies, may be necessary to manage the patient's condition.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 25-year-old nulliparous woman at 8 weeks' gestat
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 25-year-old nulliparous woman at 8 weeks' gestation comes to her physician accompanied by her husband for her first prenatal visit. She has no personal or family history of serious illness. Her vaccinations are up-to-date and she takes no medications. She has no history of recreational drug use and does not drink alcohol. Her vital signs are within normal limits. She is 167 cm (5 ft 6 in) tall and weighs 68 kg (150 lb); BMI is 24.3 kg/m2. She tested negative for HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae 4 years ago. What following tests should be done at this visit?<|eot_id|>assistant

At the first prenatal visit, several tests and screenings are recommended to ensure the health and well-being of both the mother and the fetus. Based on the information provided, here are the tests that should be considered for this 25-year-old nulliparous woman at 8 weeks' gestation:

1. **Complete Blood Count (CBC):** To check for anemia and other blood disorders.
2. **Blood Type and Rh Factor:** Determining the blood type (A, B, AB, or O) and Rh factor (positive or negative) is crucial. If the mother is Rh-negative and the father is Rh-positive, there's a possibility the baby could be Rh-positive, which may lead to complications if not managed properly.
3. **Rubella (German Measles) Titer:** To confirm immunity to rubella, as infection during pregnancy can lead to congenital rubella syndrome.
4. **Varicella (Chickenpox) Titer:** If there's no history of chickenpox or vaccination, a titer can determine immunity.
5. **Hepatitis B Surface Antigen (HBsAg):** To screen for hepatitis B infection, which can be transmitted to the baby during birth.
6. **Syphilis Screening:** Even though she tested negative 4 years ago, syphilis screening is recommended for all pregnant women at the first prenatal visit due to its potential severe consequences for the fetus if left untreated.
7. **Urine Analysis and Culture:** To check for urinary tract infections (UTIs) or asymptomatic bacteriuria, which can lead to complications in pregnancy if not treated.
8. **Pap Smear (if due):** If the patient's last Pap smear was not within the last 3 years or if she is due for a screening based on previous results, a Pap smear should be considered.
9. **Ultrasound:** An early ultrasound can confirm the gestational age, check for multiple pregnancies, and evaluate for any obvious fetal anomalies.
10. **First Trimester Screening (if applicable):** This includes a combination of ultrasound (to measure nuchal translucency) and blood tests (to measure free beta-hCG and PAPP-A) to assess the risk for chromosomal abnormalities like Down syndrome. This screening is typically offered between 11 and 14 weeks of gestation, so it might not be done at this exact visit but should be discussed and planned for the appropriate time.
11. **Glucose Screening:** Not typically done at the first visit but scheduled for between 24 and 28 weeks of gestation to screen for gestational diabetes.
12. **Group B Streptococcus (GBS) Screening:** Usually performed between 36 and 37 weeks of gestation to identify colonization, which can affect management during labor.

For someone who has not been screened recently (within the past year) for sexually transmitted infections (STIs) and considering her last negative tests were 4 years ago, it might also be recommended to repeat screenings for:

- **Chlamydia trachomatis**
- **Neisseria gonorrhoeae**
- **HIV**

However, the specific tests performed can depend on the patient's risk factors, local prevalence of diseases, and current guidelines from professional obstetric organizations such as the American College of Obstetricians and Gynecologists (ACOG).
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 33-year-old HIV-positive male is seen in clinic 
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 33-year-old HIV-positive male is seen in clinic for follow-up care. When asked if he has been adhering to his HIV medications, the patient exclaims that he has been depressed, thus causing him to not take his medication for six months. His CD4+ count is now 33 cells/mm3. What medication(s) should he take in addition to his anti-retroviral therapy?<|eot_id|>assistant

Given the patient's CD4+ count of 33 cells/mm3 and his history of not taking his antiretroviral therapy (ART) for six months, it's crucial to address both his HIV management and his mental health. For the HIV management, the patient should be restarted on ART as soon as possible. However, the question asks about additional medication(s) to his ART, implying the need to consider prophylaxis against opportunistic infections (OIs) given his significantly compromised immune system.

At a CD4+ count of 33 cells/mm3, the patient is at high risk for several opportunistic infections. The primary concerns include:

1. **Pneumocystis jirovecii pneumonia (PCP):** Prophylaxis against PCP is recommended for patients with a CD4+ count below 200 cells/mm3. The first-line prophylaxis is trimethoprim-sulfamethoxazole (TMP-SMX).

2. **Toxoplasmosis:** Prophylaxis against toxoplasmosis is recommended for patients with a CD4+ count below 100 cells/mm3. TMP-SMX is also effective for toxoplasmosis prophylaxis.

3. **Mycobacterium avium complex (MAC):** Prophylaxis against MAC is recommended for patients with a CD4+ count below 50 cells/mm3. Azithromycin is a commonly used option for MAC prophylaxis.

Given these guidelines, this patient, with a CD4+ count of 33 cells/mm3, would benefit from:

- **Trimethoprim-sulfamethoxazole (TMP-SMX)** for PCP and toxoplasmosis prophylaxis.
- **Azithromycin** for MAC prophylaxis.

Additionally, addressing his depression is crucial for his overall health and adherence to his HIV treatment regimen. Referral to a mental health professional and consideration of antidepressant medication would be appropriate. However, the question specifically asks about medications in addition to his ART, focusing on the management of his immunocompromised state.

It's also important to note that before starting any new medications, potential drug interactions with his ART regimen should be carefully considered to avoid adverse effects or reduced efficacy of either the ART or the prophylactic medications.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 30-year-old woman with HIV comes to the emergenc
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 30-year-old woman with HIV comes to the emergency department because of fever and multiple skin lesions for 1 week. She also has nausea, anorexia, and abdominal pain. The skin lesions are non-pruritic and painless. She has smoked one pack of cigarettes daily for 15 years and drinks 2 beers daily. She has been using intravenous crack cocaine for 6 years. She appears ill. Her temperature is 38°C (100.4°F), pulse is 105/min, blood pressure is 110/75 mm Hg. Her BMI is 19 kg/m2. Examination shows track marks on both cubital fossae. There are white patches on her palate that can be scraped off. There are several red papules measuring 1 to 2 cm on her face and trunk. Her CD4+T-lymphocyte count is 98/mm3 (N ≥ 500). Biopsy of a skin lesion shows vascular proliferation and small black bacteria on Warthin-Starry stain. What is the most appropriate pharmacotherapy?<|eot_id|>assistant

Based on the clinical presentation and laboratory findings, the patient is likely suffering from Bacillary Angiomatosis (BA), a condition caused by the bacteria Bartonella henselae or Bartonella quintana. The diagnosis is suggested by the presence of vascular proliferation and small black bacteria on Warthin-Starry stain in the skin biopsy.

The most appropriate pharmacotherapy for Bacillary Angiomatosis in a patient with HIV and a low CD4+ T-lymphocyte count is:

1. Erythromycin: This is the first-line treatment for BA. The recommended dose is 500 mg orally four times a day for at least 3 months.
2. Doxycycline: This is an alternative treatment option, especially for patients who are intolerant to erythromycin. The recommended dose is 100 mg orally twice a day for at least 3 months.

It's also important to note that the patient's HIV infection should be managed concurrently with antiretroviral therapy (ART) to improve her immune status and prevent further opportunistic infections.

In addition to treating the BA, the patient's other health issues, such as her substance abuse and malnutrition, should be addressed. She should be referred to a specialist for further management and support.

It's worth mentioning that the white patches on her palate that can be scraped off are likely oral thrush, a common opportunistic infection in HIV-infected patients. This can be treated with antifungal medications such as fluconazole.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 35-year-old man comes to the physician because o
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 35-year-old man comes to the physician because of a 6-month history of fatigue and increased sweating at night. He says that he feels 'constantly tired' and needs more rest than usual although he sleeps well. In the morning, his sheets are often wet and his skin is clammy. He has not had any sore throat, runny nose, or cough recently. He has not traveled anywhere. Over the past 4 months, he has had a 6.8-kg (15-lb) weight loss, despite having a normal appetite. He does not drink or urinate more than usual. He is 181 cm (5 ft 11 in) tall and weighs 72 kg (159 lb); BMI is 22 kg/m2. His temperature is 37.9°C (100.2°F), pulse is 65/min, and blood pressure is 120/70 mm Hg. Physical examination shows no abnormalities. An HIV screening test and confirmatory test are both positive. The CD4 count is 600 cells/μl and the viral load is 104 copies/mL. Treatment with lamivudine, zidovudine, and indinavir is begun. The patient is at greatest risk for what adverse effects?<|eot_id|>assistant

The patient is at greatest risk for the following adverse effects:

1. **Lactic acidosis and hepatotoxicity** from lamivudine and zidovudine (nucleoside reverse transcriptase inhibitors, NRTIs): These medications can cause mitochondrial toxicity, leading to lactic acidosis and liver damage.
2. **Nephrolithiasis (kidney stones)** from indinavir (protease inhibitor, PI): Indinavir can cause an increased risk of kidney stones due to its low solubility in urine.
3. **Lipodystrophy** from the combination of lamivudine, zidovudine, and indinavir: This combination of medications can cause changes in body fat distribution, leading to lipodystrophy (abnormal fat accumulation or loss).
4. **Gastrointestinal side effects** such as nausea, vomiting, and diarrhea from all three medications.
5. **Bone marrow suppression** from zidovudine, which can cause anemia, neutropenia, or thrombocytopenia.
6. **Peripheral neuropathy** from lamivudine and zidovudine, which can cause numbness, tingling, or pain in the hands and feet.

It's essential to note that the patient's CD4 count is relatively high (600 cells/μl), and the viral load is relatively low (10^4 copies/mL), which suggests that the patient is in the early stages of HIV infection. The treatment regimen chosen is a combination of two NRTIs (lamivudine and zidovudine) and a PI (indinavir), which was a common regimen at the time but has largely been replaced by more modern and better-tolerated regimens.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 52-year-old man is brought to the emergency depa
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 52-year-old man is brought to the emergency department because of headaches, vertigo, and changes to his personality for the past few weeks. He was diagnosed with HIV 14 years ago and was started on antiretroviral therapy at that time. Medical records from one month ago indicate that he followed his medication schedule inconsistently. Since then, he has been regularly taking his antiretroviral medications and trimethoprim-sulfamethoxazole. His vital signs are within normal limits. Neurological examination shows ataxia and apathy. Mini-Mental State Examination score is 15/30. Laboratory studies show: Hemoglobin 12.5 g/dL Leukocyte count 8400/mm3 Segmented neutrophils 80% Eosinophils 1% Lymphocytes 17% Monocytes 2% CD4+ T-lymphocytes 90/μL Platelet count 328,000/mm3 An MRI of the brain with contrast shows a solitary ring-enhancing lesion involving the corpus callosum and measuring 4.5 cm in diameter. A lumbar puncture with subsequent cerebrospinal fluid analysis shows slight pleocytosis, and PCR is positive for Epstein-Barr virus DNA. What is the most likely diagnosis?<|eot_id|>assistant

Based on the patient's symptoms, laboratory results, and imaging findings, the most likely diagnosis is Primary Central Nervous System Lymphoma (PCNSL).

Here's a breakdown of the key points that support this diagnosis:

1. **HIV diagnosis and inconsistent antiretroviral therapy adherence**: The patient's history of HIV and inconsistent adherence to antiretroviral therapy increases his risk of developing opportunistic infections and malignancies, including PCNSL.
2. **Neurological symptoms**: The patient's symptoms, such as headaches, vertigo, changes in personality, ataxia, and apathy, are consistent with a brain lesion.
3. **Low CD4+ T-lymphocyte count**: A CD4+ count of 90/μL indicates severe immunosuppression, which increases the risk of opportunistic infections and malignancies, including PCNSL.
4. **Ring-enhancing lesion on MRI**: The solitary ring-enhancing lesion involving the corpus callosum is a characteristic imaging finding in PCNSL, particularly in immunocompromised patients.
5. **Positive Epstein-Barr virus (EBV) DNA PCR in cerebrospinal fluid**: EBV is associated with PCNSL, particularly in HIV-infected patients. The presence of EBV DNA in the cerebrospinal fluid supports the diagnosis of PCNSL.
6. **Slight pleocytosis**: The presence of slight pleocytosis (increased cell count) in the cerebrospinal fluid is consistent with PCNSL.

While other conditions, such as toxoplasmosis or progressive multifocal leukoencephalopathy (PML), can also present with similar symptoms and imaging findings, the combination of the patient's HIV status, low CD4+ count, and positive EBV DNA PCR in the cerebrospinal fluid, along with the characteristic ring-enhancing lesion on MRI, makes PCNSL the most likely diagnosis.
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 2300-g (5-lb 1-oz) male newborn is delivered to 
<class 'str'> <|begin_of_text|><|start_header_id|>system<|end_header_id|>

Cutting Knowledge Date: December 2023
Today Date: 26 Jul 2024

<|eot_id|><|start_header_id|>user<|end_header_id|>

A 2300-g (5-lb 1-oz) male newborn is delivered to a 29-year-old primigravid woman. The mother has HIV and received triple antiretroviral therapy during pregnancy. Her HIV viral load was 678 copies/mL 1 week prior to delivery. Labor was uncomplicated. Apgar scores are 7 and 8 at 1 and 5 minutes respectively. Physical examination of the newborn shows no abnormalities. What is the most appropriate next step in management of this infant?<|eot_id|>assistant

Given the mother's HIV status and the fact that she received triple antiretroviral therapy during pregnancy, the risk of mother-to-child transmission (MTCT) of HIV is significantly reduced but not eliminated. The management of the infant should focus on further reducing this risk and monitoring for potential HIV infection. Here are the steps that should be considered:

1. **Administer Antiretroviral Prophylaxis to the Newborn**: The newborn should receive antiretroviral prophylaxis as soon as possible after birth, ideally within the first 6 hours of life, to reduce the risk of HIV transmission. The most commonly recommended regimen for newborns is a combination of zidovudine (AZT) for 4-6 weeks, with or without other antiretroviral drugs, depending on the mother's antiretroviral regimen and viral load close to delivery.

2. **HIV Antibody Testing**: Although the infant will have maternal antibodies, which can give a false-positive result, an HIV antibody test can be done at birth to establish a baseline. However, the definitive diagnosis of HIV in the infant requires virologic testing.

3. **Virologic Testing**: The infant should undergo virologic testing for HIV DNA or RNA at birth (or as soon as possible), at 2 weeks, at 1-2 months, and at 4-6 months of age. If any of these tests are positive, the infant is considered to have acquired HIV.

4. **Postnatal Care and Follow-Up**: Regular follow-up appointments with a pediatrician experienced in the care of HIV-exposed infants are crucial. These visits will include monitoring for signs of HIV infection, potential side effects of antiretroviral therapy, and overall health.

5. **Avoidance of HIV Post-Exposure Prophylaxis (PEP) for the Newborn Unless Indicated**: PEP is not routinely recommended for newborns born to HIV-positive mothers who have received effective antiretroviral therapy during pregnancy unless there was a significant breach in the preventive measures (e.g., no antiretroviral therapy during pregnancy, high viral load at delivery, or other factors that increase transmission risk).

6. **Safe Feeding Practices**: The mother should be advised against breastfeeding to prevent postnatal transmission of HIV, as breast milk can transmit the virus. Formula feeding should be recommended in settings where it is feasible, safe, and sustainable.

In summary, the most appropriate next step in the management of this infant is to administer antiretroviral prophylaxis (such as zidovudine) as soon as possible, followed by virologic testing for HIV, and to ensure close follow-up with a pediatrician experienced in the care of HIV-exposed infants. Additionally, advising against breastfeeding and ensuring the infant receives formula feeding is crucial to prevent postnatal transmission of HIV.
Saved Llama answers (category=4, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/Llama_cluster/Llama_answers_category_4.1_HIV_EQ.json
You shouldn't move a model that is dispatched using accelerate hooks.
E0117 15:27:49.641000 22589460875072 torch/distributed/elastic/multiprocessing/api.py:826] failed (exitcode: -9) local_rank: 0 (pid: 3453901) of binary: /cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/python-3.11.6-ukhwpjnwzzzizek3pgr75zkbhxros5fq/bin/python3
I0117 15:27:49.669000 22589460875072 torch/distributed/elastic/multiprocessing/errors/__init__.py:360] ('local_rank %s FAILED with no error file. Decorate your entrypoint fn with @record for traceback info. See: https://pytorch.org/docs/stable/elastic/errors.html', 0)
Traceback (most recent call last):
  File "/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/python-3.11.6-ukhwpjnwzzzizek3pgr75zkbhxros5fq/bin/torchrun", line 10, in <module>
    sys.exit(main())
             ^^^^^^
  File "/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/python-3.11.6-ukhwpjnwzzzizek3pgr75zkbhxros5fq/lib/python3.11/site-packages/torch/distributed/elastic/multiprocessing/errors/__init__.py", line 347, in wrapper
    return f(*args, **kwargs)
           ^^^^^^^^^^^^^^^^^^
  File "/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/python-3.11.6-ukhwpjnwzzzizek3pgr75zkbhxros5fq/lib/python3.11/site-packages/torch/distributed/run.py", line 879, in main
    run(args)
  File "/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/python-3.11.6-ukhwpjnwzzzizek3pgr75zkbhxros5fq/lib/python3.11/site-packages/torch/distributed/run.py", line 870, in run
    elastic_launch(
  File "/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/python-3.11.6-ukhwpjnwzzzizek3pgr75zkbhxros5fq/lib/python3.11/site-packages/torch/distributed/launcher/api.py", line 132, in __call__
    return launch_agent(self._config, self._entrypoint, list(args))
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/python-3.11.6-ukhwpjnwzzzizek3pgr75zkbhxros5fq/lib/python3.11/site-packages/torch/distributed/launcher/api.py", line 263, in launch_agent
    raise ChildFailedError(
torch.distributed.elastic.multiprocessing.errors.ChildFailedError: 
========================================================
get_model_answers_and_prompt_generation.py FAILED
--------------------------------------------------------
Failures:
  <NO_OTHER_FAILURES>
--------------------------------------------------------
Root Cause (first observed failure):
[0]:
  time      : 2025-01-17_15:27:49
  host      : eu-ts-01.euler.ethz.ch
  rank      : 0 (local_rank: 0)
  exitcode  : -9 (pid: 3453901)
  error_file: <N/A>
  traceback : Signal 9 (SIGKILL) received by PID 3453901
========================================================
slurmstepd: error: Detected 1 oom_kill event in StepId=21073161.0. Some of the step tasks have been OOM Killed.
srun: error: eu-ts-01: task 0: Out Of Memory
